Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY1 of 115   Clinical Study Protocol  
 Study Intervention AZD7442 
 Study Code D8851C00001  
 Version 7.0 
 Date 30 June 2021 
   
   
       
A Phase III Randomized, Double- blind, Placebo-controlled, 
Multicenter Study to Determin e the Safety and Efficacy of 
AZD7442 for the Treatment of COVID-19 in Non-hospi[INVESTIGATOR_198602]: [COMPANY_008] AB  
Legal Registered Address:  151, 85 S√∂dert√§lje, Sweden 
Regulatory Agency Identifier Number(s): EudraCT Number: 2020-005315-[ADDRESS_237036] procedures. The Clinical Study Protocol  is publicly registered and the results are 
disclosed and/or published according to the Astr aZeneca Global Policy on Bioethics and in 
compliance with prevaili ng laws and regulations. 
  
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY2 of 115  Protocol Number:  D8851C00001 
Amendment Number:  Amendment 6 
Study Intervention:  AZD7442, a combination product of 2 monoclonal antibodies 
(AZD8895 and AZD1061) 
Study Phase:  Phase III 
Short Title:  Phase III Double-blind, Placebo-controlled  Study of AZD7442 for Treatment of 
COVID-19 in Outpatient Adults 
Acronym : TACKLE (Treating acute COVID-19 condi tion with a long hal f-life engineered 
antibody) 
Study Physician Name [CONTACT_9352] [CONTACT_198645]-ordinating Investigator:  [CONTACT_198696], University College 
London, [LOCATION_006] 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY4 of 115  EDVHOLQH¬î'D\  for isolation purposes. 
Early intervention analysis 
set All participants in the modi fied full analysis set who 
UHFHLYHG,03¬îGD\VIURPV\PSWRP onset. 
Seronegative analysis set All participants in  the modified full an alysis set who were 
seronegative at baseline. 
 
Synopsis, Sections 1.2 (Schema), 4.1 (Study Design), 9.1 (Statistical Hypotheses), 9.4.1 
(General Considerations) : The number of primary endpoint events required for the 
primary analysis has been reduced from 52 to 43 and this will be sufficient to provide 90% 
power for the primary analysis. The data cut- off for the primary analysis will be [ADDRESS_237037] been 
confirmed in the primary  analysis population. 
Synopsis, Section 9.2 (Sample Size Determination) : Statistical power has been reduced 
from 95% to 90%, resulting in th e number of events required for the primary analysis being 
reduced from 52 to 43. 
Section 9.3 (Populations for Analysis):  Analysis populations have been defined to 
accommodate the clarification of the primar y endpoint population and the inclusion of 
additional supportive estimands. 
Section 9.4.1 (General Considerations):  The data cut off has been changed to reflect the 
change in sample size from 52 to 43 primary endpoint events in the primary analysis 
population.  
Section [IP_ADDRESS] (Primary Endpoint) : Primary analysis method  has been changed from 
Poisson regression model to CMH method. A dditional supportive estimands have been 
included in the multiple testing hierarchy. 
Section [IP_ADDRESS] (Secondary Endpoint) : Analysis population for secondary endpoint has 
been changed in line with the clarific ation of the primary analysis population. 
Section 9.4.5 (Methods for Multiple Testing Control):  Additional supportive estimands 
have been included in the mu ltiple testing hierarchy. 
Section 9.4.6 (Sensitivity Analyses): Clarification has been added to the analysis method in 
line with the change to the primary analysis method. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY5 of 115   
Previous amendments are summarized in Appendix I. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY6 of 115  TABLE OF CONTENTS 
TITLE PAGE .................................................................................................................... ......... 1  
PROTOCOL AMENDMENT SUMMARY  OF CHANGES TABLE...................................... 3  
TABLE OF CONTENTS .......................................................................................................... 6  
1 PROTOCOL SUMMARY ................................................................................... 10  
1.1 Synopsis ................................................................................................................ 10  
1.2 Schema .................................................................................................................. 15  
1.3 Schedule of Activities ........................................................................................... 16  
2 INTRODUCTION ................................................................................................ 25  
2.1 Study Rationale ..................................................................................................... 25  
2.2 Background ........................................................................................................... 26  
2.3 Benefit/Risk Assessment ...................................................................................... 26  
2.3.1  Risk Assessment ................................................................................................... 26  
2.3.2  Benefit Assessment ............................................................................................... 27  
2.3.3  Overall Benefit:Risk Conclusion .......................................................................... 27  
3 OBJECTIVES AND ENDPOINTS ...................................................................... 27  
4 STUDY DESIGN ................................................................................................. 30  
4.1 Overall Design ...................................................................................................... 30  
4.2  32 
4.3  34 
4.4 End of Study Definition ........................................................................................ 35  
5 STUDY POPULATION ....................................................................................... 35  
5.1 Inclusion Criteria .................................................................................................. 35  
5.2 Exclusion Criteria ................................................................................................. 38  
5.3 Lifestyle Considerations ....................................................................................... 40  
5.4 Screen Failures ..................................................................................................... 40  
6 STUDY INTERVENTION .................................................................................. 40  
6.1 Investigational Medicinal Products Administered ............................................... 40  
6.1.1  Investigational Medicinal Products ...................................................................... 40  
6.2 Preparation/Handling/Storage/Accountability ...................................................... 41  
6.2.1  Dose Preparation and Adminis tration Instructions ............................................... 42  
6.3 Measures to Minimize Bias: Ra ndomization and Blinding .................................. [ADDRESS_237038] Compliance ................................................... 43  
6.5 Concomitant Therapy ........................................................................................... 43  
6.5.1  COVID-19 Vaccination ........................................................................................ 45  CCI
CCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY7 of 115  6.6 Dose Modification ................................................................................................ 46  
6.7 Intervention After the End of the Study ............................................................... 46  
7 DISCONTINUATION OF IMP AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL ............................................................ [ADDRESS_237039] to Follow-up ................................................................................................. 47  
7.4 Study Suspension/Early Termination ................................................................... [ADDRESS_237040]/Update Secondary Contacts ..................................................................... 50  
8.1.3  Survival Status Check ........................................................................................... 50  
8.1.4  Participant-reported Symptom Diary .................................................................... 50  
8.1.5  Return to Usual Health ......................................................................................... 52  
8.1.6   52 
8.1.7  Virologic Studies .................................................................................................. 52  
8.2 Safety Assessments ............................................................................................... 52  
8.2.1  Physical Examinations .......................................................................................... 52  
8.2.2  Vital Signs ............................................................................................................ 53  
8.2.3  Electrocardiograms ............................................................................................... 53  
8.2.4  Clinical Safety Laboratory Assessments .............................................................. 53  
[IP_ADDRESS]  Females Only ........................................................................................................ 55  
8.2.5  Injection Site Inspection ....................................................................................... 55  
[IP_ADDRESS]  Monitoring After IMP Administration .................................................................. [ADDRESS_237041] ....................................................................... 58  
8.3.5  Adverse Events Based on Signs and Symptoms .................................................. 59  
8.3.6  Adverse Events Based on Examinations and Tests .............................................. 59  
8.3.7  Hy‚Äôs Law .............................................................................................................. 59  
8.3.8  Disease Under Study ............................................................................................ 60  
8.3.9  Reporting of Serious Adverse Events ................................................................... 60  
8.3.10  Pregnancy ............................................................................................................. 61  
[IP_ADDRESS]  Maternal Exposure ................................................................................................ 61  
[IP_ADDRESS]  Paternal Exposure ................................................................................................. 62  
8.3.11  Medication Error ................................................................................................... 62  
8.4 Overdose ............................................................................................................... 62  
8.5 Human Biological Samples .................................................................................. 63  
8.5.1  Pharmacokinetics Assessments ............................................................................ 63  
[IP_ADDRESS]  Determination of Drug Concentration .................................................................. [ADDRESS_237042] OF APPENDICES 
Appendix A  Regulatory, Ethical, and Study Oversight Considerations .......................... 76  
Appendix B  Adverse Events: Definitions and Pr ocedures for Recording, Evaluating, 
Follow-up, and Reporting ........................................................................... 82  
Appendix C  Handling of Human Biological Samples ..................................................... 87  
Appendix D  Actions Required in Cases of In creases in Liver Biochemistry and 
Evaluation of Hy‚Äôs Law .............................................................................. 89  
Appendix E  Abbreviations .............................................................................................. 95  
Appendix F  WHO Clinical Progression Scale for COVID-19 ....................................... 98  
Appendix G  Participant-reported Symptom Diary .......................................................... 99  
Appendix H  Hospi[INVESTIGATOR_198603] ......................................................................... 105  
Appendix I  Amendment History .................................................................................. 106  
 CCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY12 of 115  ADA Anti-drug-antibody; AE Adverse event; AESI Adverse event of special interest; AUC  Area under the 
plasma concentration-time curve; COVID-19, Coronavirus disease 2019; ECMO Extracorporeal membrane 
oxygenation; IM Intramuscular; IMP Investigational medicinal product; PK Pharmacokinetic; RNA Ribonucleic acid; SAE Serious adverse event; SARS-CoV-2 Severe acute respi[INVESTIGATOR_7686]-coronavirus-2; SpO2 Oxygen 
saturation; WHO World Health Organization. 
 
 
Overall Design 
This is a Phase III, randomized, double-b lind, placebo-controlled, mu lticountry, multicenter 
study assessing the safety and efficacy of a single [ADDRESS_237043] of 2 monoclonal 
antibodies (AZD8895 and AZD1061), administered as [ADDRESS_237044] of care therapy (according to 
participating institution/hospi[INVESTIGATOR_17399] l) regardless of the study trea tment group to which they are 
randomized. Approximately 130 to 140 s ites will participate in this study. 
3DUWLFLSDQWVZLOOEHRXWSDWLHQW DGXOWV¬ï\HDUVZLWKDGRFX PHQWHGSRVLWLYH6$56 -CoV-2 
PROHFXODUWHVW DQWLJHQRUQXFOHLFDFLG IURPDVDPSOH FROOHFWHG¬îGD\VSULRUWRVWXG\HQWU\
DQGZLWK¬îGD\ s of symptoms of COVID-19 at study en try (‚ÄòDay 1‚Äô symptom count starts 
from the first day of symptoms), plus the presence of select sy mptoms within [ADDRESS_237045] 60% of participants will meet the protocol definition of being at high-risk of 
progression to severe COVID-19 as defined by [CONTACT_39132]: 
x Persons aged 65 years and older at randomization 
x Persons aged < [ADDRESS_237046] one of the following conditions: 
 Cancer 
 Chronic lung disease or m oderate to severe asthma 
 Obesity (BMI > 30; may be based on self -report of recent height and weight 
measurement) 
 Hypertension 
 Cardiovascular disease (inc luding history of stroke) 
 Diabetes 
 Chronic kidney disease 
 Chronic liver disease 
 Immunocompromised state from solid organ transpla nt, blood or bone marrow 
transplant, immune deficien cies, HIV, use of corticosteroids, or use of other 
immunosuppressive medicines CCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY13 of 115   Sickle cell disease 
 Smoking (current or former) 
 
Randomization will be stratified (using centralized blocked randomization) by: 
1 7LPHIURPV\PSWRPRQVHW¬î  5 days versus > 5 days) 
2 High-risk versus low-risk of progression to se vere COVID-19 (high-ri sk is defined above) 
 
The enrollment of low-risk  participants has stopped. 
Up to approximately 1700 participants will be ra ndomized in a 1:1 ratio to receive a single IM 
dose of 600 mg of AZD7442 (n = up to a pproximately 850) or placebo (n = up to 
approximately 850) on Day 1. The first 20 participants to be dosed (approximately 
10 allocated to the AZD7442 group and 10 allocat ed to placebo) will form a sentinel group. 
After the entire sentinel group ha s been dosed, further enrollment  will pause until the sentinel 
group‚Äôs safety data through Day 8 has been re viewed by [CONTACT_198646] a 
recommendation to continue or to ha lt dosing of additional participants. 
Participants will be enrolled into one of 2 independent cohorts: 
x Cohort 1 (n = approximately 300), which wi ll include the sentinel group, will undergo 
more intensive testing to char acterize their viro logical and immunologi cal status, and to 
correlate that status with clinical outcomes. 
x Cohort 2 (n = up to approximately 1400) will be followed for clinical outcomes. 
 
Following screening, and no more than 7 days (‚ÄòDay 1‚Äô sympto m count starts from the first 
day of symptoms) from self-reported onset of  COVID-19-related symptoms or measured 
fever, participants will receive a single dose of IMP. The dose will be administered as 2 
separate IM injections (one  for AZD8895 and one for AZD1061; the 2 compounds will not be 
co-administered) in the gluteal region. In Cohort 1, the first 20  participants dosed (ie, the 
sentinel group) will undergo safety monitori ng for [ADDRESS_237047] participant in the sentinel group before the next pa rticipant can be dosed. The next 80 
participants (21 to 100) will then unde rgo safety monitoring for [ADDRESS_237048] IMP administration, 
otherwise the minimum safety monitoring time will be 1 hour. In addition, the sentinel group 
will be contact[CONTACT_198647] (in-person or by [CONTACT_94725]) for the first [ADDRESS_237049] access to emergency kits for treatment of severe anaphylactic 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY14 of 115  reactions/shock and to medical staff tr ained in using these emergency kits.  
After administration of the dose of study inte rvention on Day 1, participants will undergo 
28 days of intensive follow-up, followed by [CONTACT_198648]-up through Day 457.  
Disclosure Statement : This is a parallel-group treatment  study with 2 arms that are 
double-blind.  
Number of Participants:  CRM [ADDRESS_237050] 60% of participants will meet the protocol definition 
of being at high-risk of progression to severe COVID- 19. Enrollment will stop when 
approximately [ADDRESS_237051]  been confirmed in the primary analysis 
population. 
Note : ‚ÄúEnrolled‚Äù means a participant‚Äôs, or their legally acceptable representative‚Äôs, agreement 
to participate in a clinical  study following completion of th e informed consent process. 
Potential participants who are screened for the purpose of determining eligibility for the study, 
but are not randomly assigned in the study, are considered ‚Äúscreen failures‚Äù, unless otherwise 
specified by [CONTACT_760].  
Intervention Groups and Duration:  Participants will be randomized in a 1:[ADDRESS_237052]:  Yes 
Statistical Methods 
Primary Endpoint: The primary efficacy endpoint is a co mposite of either severe COVID-19 
or death from any cause through Day 29. Severe COVID-19 is ch aracterized by a minimum of 
either pneumonia (fever, cough, tachypnea, or dy spnea, AND lung infiltrates) or hypoxemia 
(SpO 2 < 90% in room air and/or severe respi[INVESTIGATOR_196675]) and a WHO Clinical Progression 
Scale score of 5 or higher (Appendix F). 
Sample Size: Up to approximately 1700 participants will be randomized in a 1:1 ratio to 
receive a single 600 mg IM dose of AZD7442 (n = up to approximately 850) or placebo (n = 
up to approximately 850) on Day 1. 
The study has  to detect a RRR of  in the incidence of severe COVID-19/death 
in the AZD7442 group compared to the placebo group,  
.  
All participants will re main in the study for up to [ADDRESS_237053] completed the study (ie, all partic ipants have completed 
Day 457 visit, see Figure 1).
The study will be completely double-blind until the primary analysis (ie, blind for participants, 
Investigators/site staff, and Sponsor/designated clinical rese arch organization). The site 
personnel, participants, and the st udy team members who participat e in the advice or decisions 
involving study conduct or day-to-day interactions  with the site, will re main blinded until the 
end of the study (ie, all particip ants have completed Day 457 visit)  to ensure the trial integrity 
is maintained.
1.[ADDRESS_237054]; IM Intramuscular

Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY16 of 115  1.3 Schedule of Activities 
The SoA for Cohort 1 is in Table 1 and the SoA for Cohort 2 is in Table 2. 
Table 1 Schedule of Acti vities for Cohort 1 
Procedure Screening 
 
Day -1 or 
Day 1 Treatment and Follow-up Period Early 
Discontinuation 
Visit Details 
in 
Section 
of CSP 
Day 
1 Day 
3 Day 
6 Day
8 Day 
15 Day 
29 Day 
85 Day 
169 Day 
366 Day 457 Before 
Day 29 After 
Day 
29 
Window (days)  NA ¬± 1 ¬± 1 ¬± 1 ¬± 2 ¬± 4 ¬± 7 ¬± 7 ¬± 7 ¬± 7    
P = In-Person Visit 
H = Home Visit 
R = Remote Visit P P P/Ha P/Ha R P/Ha P P P P P/R P P  
Informed consent X               
Assignment SID number X               
Documentation of SARS-CoV-2 
infection  X              
Respi[INVESTIGATOR_198604]-CoV-2 Xb              
COVID-19 Symptom screen X             5 . 1  
Medical/medication history X              
Risk categorization X              4 . 1  
Smoking status X               
Clinical assessments X X X X  X X X X X  X X 8.1.1 
Complete physical examinationd X         X  X X 8.2.1 
Targeted physical  examination  X Xc Xc  Xc X X X     8.2.1 
Vital signs X Xe X X  X X X X X  X X 8.2.2 
Triplicate 12-lead ECG X      X   X  X X 8.2.3 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY17 of 115  Table 1 Schedule of Acti vities for Cohort 1 
Procedure Screening 
 
Day -1 or 
Day 1 Treatment and Follow-up Period Early 
Discontinuation 
Visit Details 
in 
Section 
of CSP 
Day 
1 Day 
3 Day 
6 Day
8 Day 
15 Day 
29 Day 
85 Day 
169 Day 
366 Day 457 Before 
Day 29 After 
Day 
29 
Window (days)  NA ¬± 1 ¬± 1 ¬± 1 ¬± 2 ¬± 4 ¬± 7 ¬± 7 ¬± 7 ¬± 7    
P = In-Person Visit 
H = Home Visit 
R = Remote Visit P P P/Ha P/Ha R P/Ha P P P P P/R P P  
Hematology  Xf,g Xg Xg  Xg Xg  X X  Xg X 8.2.4 
Serum chemistry panel  Xf X X  X X  X X  X X 8.2.4 
Serum sample for vitamin Do  Xf            [IP_ADDRESS] 
Serum sample for zinco  Xf            [IP_ADDRESS] 
Urinalysis  Xf  X  X X  X X  X X 8.2.4 
Pregnancy testingi Xf,h Xf,h  X   X X X X  X X [IP_ADDRESS] 
Concomitant medications X X X X X X X X X X  X X 6.[ADDRESS_237055]/update secondary contacts  X X X X X X       8.1.2 
Verify eligibility criteria X X            5.1, 5.2 
Randomization  X            6.3.1 
Survival status check   X X  X X X X X  X X 8.1.3 
Participant-reported symptom diaryj  Daily through Day 29       8.1.4 
Participant-reported symptom 
reminderk  Daily through Day 29       8.1.4 
Staff review of participant-reported 
symptom diary   X X  X X     X  8.1.4 
Retrieval of participant-reported 
symptom diary        Xl     X  8.1.4 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY18 of 115  Table 1 Schedule of Acti vities for Cohort 1 
Procedure Screening 
 
Day -1 or 
Day 1 Treatment and Follow-up Period Early 
Discontinuation 
Visit Details 
in 
Section 
of CSP 
Day 
1 Day 
3 Day 
6 Day
8 Day 
15 Day 
29 Day 
85 Day 
169 Day 
366 Day 457 Before 
Day 29 After 
Day 
29 
Window (days)  NA ¬± 1 ¬± 1 ¬± 1 ¬± 2 ¬± 4 ¬± 7 ¬± 7 ¬± 7 ¬± 7    
P = In-Person Visit 
H = Home Visit 
R = Remote Visit P P P/Ha P/Ha R P/Ha P P P P P/R P P  
Return to usual (pre-COVID-19) 
health   X X X X X X X   X X 8.1.5 
Household infection report   X     X X X   X X 8.1.6 
Study staff-collected mid-turbinate 
nasal swab for SARS-CoV-2 RT-
PCR and sequencingm  Xf X X  X X      X  8.1.7 
 
Serum for SARS-CoV-2 serology  Xn X X  X X X X X  X X [IP_ADDRESS] 
 
 
Serum for AZD7442 
pharmacokinetics  Xn X X  X X X X X X 
[optional] X X 8.5.1 
Serum for AZD7442 anti-drug 
antibodies  Xf     X X X X X 
[optional] X  [IP_ADDRESS] 
 
 
 
 CCI CCI
CCICCI
CCI
CCI
CCICCI
CCI
CCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY19 of 115  Table 1 Schedule of Acti vities for Cohort 1 
Procedure Screening 
 
Day -1 or 
Day 1 Treatment and Follow-up Period Early 
Discontinuation 
Visit Details 
in 
Section 
of CSP 
Day 
1 Day 
3 Day 
6 Day
8 Day 
15 Day 
29 Day 
85 Day 
169 Day 
366 Day 457 Before 
Day 29 After 
Day 
29 
Window (days)  NA ¬± 1 ¬± 1 ¬± 1 ¬± 2 ¬± 4 ¬± 7 ¬± 7 ¬± 7 ¬± 7    
P = In-Person Visit 
H = Home Visit 
R = Remote Visit P P P/Ha P/Ha R P/Ha P P P P P/R P P  
 
 
IMP administration   X             [ADDRESS_237056] for safety 
monitoringr  Daily           [IP_ADDRESS] 
a Visits noted P/H can be performe d either in-person at clinical  site or at home depending on the participant‚Äôs clinical status, availability of safe transfer to sites (eg, to avoid 
risk of infection spread), and local guide lines for travel restrictions /social distancing. For home visits, a nurse or HCP trai ned on study procedures will visit the participant at 
home; nasal swabs, blood collecti on (where at-home collection is possible), and inspection of injection sites will be performed  by [CONTACT_198649]. Nurse or HCP will 
ensure shipment of specimens collecte d and reporting of AEs to study sites. 
b Perform if no documentation of SARS-CoV-2 infection available; tested locally. 
c Assessment will be performed only for participants attending i n-person visits, or if a nurse or HCP visiting the participant at  home is properly trained for these assessments. 
d Height is recorded only at the screening visit. 
e Perform pre-dose and 15 minutes (¬± 5 minutes) after both injections are complete. 
f Perform pre-dose on Day 1. 
g Hematology panel includes coagulation markers. 
h Urine pregnancy test (local laboratory) at screening. Perform another urine test (lo cal laboratory) on Day [ADDRESS_237057] was performed on  Day -1. Single serum 
(central laboratory) must be performed on Day 1. Sample urine test must return negative result before dosing.  
i Urine pregnancy test (local laboratory). 
j Participants will report COVID -19-related symptoms daily in an electronic de vice, starting pre-dose and post-dose on Day 1. CCI CCI
Clinical Study Protocol - 7.[ADDRESS_237058] ronic device. 
l If Day 29 visit is conducted earlier in ¬± [ADDRESS_237059]-dose sample (ie, sa mples obtained prior to and upon completion of  IMP administered via IM injections o n Day 1). 
o Serum vitamin D, serum zi nc,  dependent on availability of laboratory kits. 
p Perform 30 minutes (¬± 10 minutes) after the IMP has been administer ed and just prior to release from the study site or departur e of the study staff.  
q If evidence of injection site reaction persis ts at the Day [ADDRESS_237060] 20 participants dosed (ie, the sentinel group) will  undergo safety monitoring for [ADDRESS_237061] participant in the sentinel group before the next participant c an be dosed. The next 80 par ticipants (21 to 100) will 
then undergo safety monitoring for [ADDRESS_237062] IM P administration, otherwise the minimum safe ty monitoring time will be 1 hour. In a ddition, the sentinel group will be contact[CONTACT_198650] (in-person or by [CONTACT_756]) for the first 4 days after IMP administration. Contac t will be made by [CONTACT_198651]-person visit. 
s At Day 457 AE/SAE/AESI assessment will be made by [CONTACT_198652].  
Note: Remote (denoted by R) visit: either a phon e call, or a web-based virtual assessment.  
Note: Day [ADDRESS_237063]; COVID-19 Coronavirus disease 2019; CSP Clinical  Study Protocol; ECG Electrocardiogram;  HCP Healthcare personnel; IM 
Intramuscular; IMP Investigational medicinal product; NA Not a pplicable; Nab Neutralizing an tibody; NP Nasopharyngeal;  RNA 
Ribonucleic acid; RT-PCR Reverse transcriptio n polymerase chain reaction; SAE Serious adverse event; SARS-CoV-2 Severe acute re spi[INVESTIGATOR_6507] 2; SID 
Subject identification number. 
 
  CCI
CCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY21 of 115  Table 2 Schedule of Acti vities for Cohort 2 
Procedure Screening 
 
Day -1 or 
Day 1 Treatment and Follow-up Period Early 
Discontinuation 
Visit Details 
in 
Section 
of CSP Day 
1 Day 
6 Day 
8  Day 
29 Day 
85 Day 
169 Day 
366 Day 457 Before 
Day 29 After 
Day 
29 
Window (days)  NA ¬± 1 ¬± 1 ¬± 4 ¬± 7 ¬± 7 ¬± 7 ¬± 7    
P = In-Person Visit 
H = Home Visit 
R = Remote Visit P P P/Ha R P P P P P/R P P  
Informed consent X            
Assignment SID number X            
Documentation of SARS-CoV-2 infection  X            
Respi[INVESTIGATOR_198605]-CoV-2 Xb            
COVID-19 Symptom screen X           5.1 
Medical/medication history X            
Risk categorization X           4.[ADDRESS_237064] X            
Clinical assessments X X X  X X X X  X X 8.1.1 
Complete physical examinationd X       X  X X 8.2.1 
Targeted physical  examination  X Xc  X X X     8.2.1 
Vital signs X Xe X  X X X X  X X 8.2.2 
Triplicate 12-lead ECG X    X   X  X X 8.2.3 
Hematology  Xf,g Xg  Xg  X X  Xg X 8.2.4 
Serum chemistry panel  Xf X  X  X X  X X 8.2.4 
Serum sample for vitamin Dh  Xf          [IP_ADDRESS] 
Serum sample for zinch  Xf          [IP_ADDRESS] 
Urinalysis  Xf X  X  X X  X X 8.2.4 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY22 of 115  Table 2 Schedule of Acti vities for Cohort 2 
Procedure Screening 
 
Day -1 or 
Day 1 Treatment and Follow-up Period Early 
Discontinuation 
Visit Details 
in 
Section 
of CSP Day 
1 Day 
6 Day 
8  Day 
29 Day 
85 Day 
169 Day 
366 Day 457 Before 
Day 29 After 
Day 
29 
Window (days)  NA ¬± 1 ¬± 1 ¬± 4 ¬± 7 ¬± 7 ¬± 7 ¬± 7    
P = In-Person Visit 
H = Home Visit 
R = Remote Visit P P P/Ha R P P P P P/R P P  
Pregnancy testingj Xf,i Xf,i X  X X X X  X X [IP_ADDRESS] 
Concomitant medications X X X X X X X X  X X 6.[ADDRESS_237065]/update secondary contacts  X X X X       8.1.2 
Verify eligibility criteria X X          5.1, 5.2 
Randomization  X          6.3.1 
Survival status check   X  X X X X  X X 8.1.3 
Participant-reported symptom diaryk  Daily through Day 29       8.1.4 
Participant-reported symptom reminderl  Daily through Day 29       8.1.4 
Staff review of participant-reported 
symptom diary   X  X     X  8.1.4 
Retrieval of participant-reported symptom 
diary      Xm     X  8.1.4 
Return to usual (pre-COVID-19) health   X X X X X   X X 8.1.5 
 
Study staff-collected mid-turbinate nasal 
swab for SARS-CoV-2 RT-PCR and 
sequencingn  Xf X  X      X  8.1.7 
 
Serum for SARS-CoV-2 serology  Xo X  X X X X  X X [IP_ADDRESS] CCI
CCI CCICCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY23 of 115  Table 2 Schedule of Acti vities for Cohort 2 
Procedure Screening 
 
Day -1 or 
Day 1 Treatment and Follow-up Period Early 
Discontinuation 
Visit Details 
in 
Section 
of CSP Day 
1 Day 
6 Day 
8  Day 
29 Day 
85 Day 
169 Day 
366 Day 457 Before 
Day 29 After 
Day 
29 
Window (days)  NA ¬± 1 ¬± 1 ¬± 4 ¬± 7 ¬± 7 ¬± 7 ¬± 7    
P = In-Person Visit 
H = Home Visit 
R = Remote Visit P P P/Ha R P P P P P/R P P  
 
Serum for AZD7442 pharmacokinetics  Xo X  X X X X X 
[optional] X X 8.5.1 
Serum for AZD7442 anti-drug antibodies  Xf   X X X X X 
[optional] X  [IP_ADDRESS] 
 
IMP administration   Xp          6 
Check injection sites  Xq Xr         8.2.5 
Adverse events  X X X X X X X Xs X X 8.3 
SAEs and AESIs X X X X X X X X Xs X X 8.3 
8.3.4 
a Visits noted P/H can be performe d either in-person at clinical  site or at home depending on the participant‚Äôs clinical status, availability of safe transfer to sites (eg, to avoid 
risk of infection spread), and local guide lines for travel restrictions /social distancing. For home visits, a nurse or HCP trai ned on study procedures will visit the participant at 
home; nasal swabs, blood collecti on (where at-home collection is possible), and inspection of injection sites will be performed  by [CONTACT_198649]. Nurse or HCP will 
ensure shipment of specimens collecte d and reporting of AEs to study sites. 
b Perform if no documentation of SARS-CoV-2 infection available; tested locally. 
c Assessment will be performed only for participants attending i n-person visits, or if a nurse or HCP visiting the participant at  home is properly trained for these assessments. 
d Height is recorded only at the screening visit. 
e Perform pre-dose and 15 minutes (¬± 5 minutes) after both injections are complete. 
f Perform pre-dose on Day 1. 
g Hematology panel includes coagulation markers. CCI
CCICCI
CCI
Clinical Study Protocol - 7.[ADDRESS_237066] (local laboratory) at screening. Perform another urine test (lo cal laboratory) on Day [ADDRESS_237067] was performed on  Day -1. Single serum 
(central laboratory) must be performed on Day 1. Sample urine test must return negative result before dosing.  
j Urine pregnancy test (local laboratory). 
k Participants will report COVID -19-related symptoms daily in an electronic device, starting pre-dose and post-dose on Day 1. 
l Participant will be reminded every day through Day [ADDRESS_237068] ronic device. 
m If Day 29 visit is conducted earlier in ¬± [ADDRESS_237069]-dose sample (ie, sa mples obtained prior to and upon completion of  IMP administered via IM injections o n Day 1). 
p After the sentinel group is dosed, the next 80 participants dosed  (21 to 100) will undergo safety monitoring for [ADDRESS_237070] IMP ad ministration, otherwise the minimum safety 
monitoring time will be 1 hour. 
q Perform 30 minutes (¬± 10 minutes) after the IMP has been administer ed and just prior to release from the study site or departur e of the study staff. 
r If evidence of injection site reaction persis ts at the Day 6 visit, the injection site  will be rechecked at each visit until no  evidence of an active reaction remains. 
s At Day 457 AE/SAE/AESI assessmen t will be made by [CONTACT_198652]. 
t Current or former smoking status to be captured. 
Note: Remote (denoted by R) visit: either a phon e call, or a web-based virtual assessment.  
Note: Day [ADDRESS_237071]; COVID-19 Coronavirus disease 2019; CSP Clinical  Study Protocol; ECG Electrocardiogram;  HCP Healthcare personnel; IM 
Intramuscular; IMP Investigational medicina l product; NA Not applicable; Nab Neutrali zing antibody; NP Nasopharyngeal; RNA Ribo nucleic acid; RT-PCR Reverse transcription 
polymerase chain reaction; SAE Serious adve rse event; SARS-CoV-2 Severe acute respir atory syndrome coronavirus 2; SID Subject i dentification number. 
 
 
Clinical Study Protocol - 7.[ADDRESS_237072] emerge d in China in November 2019 causing cases 
of atypi[INVESTIGATOR_198606]. As of 6 October 2020, the virus has spread to a ll corners of the globe, 
with over 35 million confirmed cases reported an d more than one million associated deaths 
(Tamhane et al 2018 and WHO 2020). The C OVID-19 pandemic is causing major disruption 
to global healthcare systems with si gnificant socioeconomic impacts.  
Effective interventions to prevent or treat COVID-19 remain few in  number and clinical 
experience is limited.  
As a response to the ongoing pandemic, AstraZen eca is developi[INVESTIGATOR_198607]-CoV-2 
spi[INVESTIGATOR_144870]. The SARS-CoV-2 spi[INVESTIGATOR_198608]‚Äôs RBD, which enables the 
virus to bind to receptors on human cells. By [CONTACT_198653] e virus‚Äôs spi[INVESTIGATOR_144870], 
antibodies can block the virus‚Äôs attachment to hu man cells, and, therefore, is expected to block 
infection.  
AZD7442, a combination of 2 of these mAbs  (AZD8895 and AZD1061), is being evaluated 
for administration to treat or  prevent COVID-19. There is cu rrently one ongoing Phase I study 
with AZD7442 (study D8850C00001) and 2 ong oing Phase III prophylaxis studies (a 
pre-exposure prophylaxis of COVID- [ADDRESS_237073]-exposure 
prophylaxis of COVID-19 study D8850C00003), in  addition to this treatment study. 
Further details about AZD7442 are provided throughout this se ction and in the AZD7442 IB. 
2.[ADDRESS_237074] been engineered with triple am ino acid substitutions  M252Y/S254T/T256E (YTE) 
in the Fc region to prolong the half-life, which is expected to provide protection from 
COVID-[ADDRESS_237075] 5 months. In addition, the tr iple amino acid substitutions 
L234F/L235E/P331S I in the Fc region were e ngineered for both AZD8895 and AZD1061 to 
abrogate Fc mediated effector  function, which is expected to reduce theoretical risk of 
antibody-dependent enhancement. The purpose of  this Phase III study is to determine if 
AZD7442 can safely treat COVID-[ADDRESS_237076] cells during coronavirus infection 
via different receptors (Li 2016). SARS-CoV-2 belongs to the phylogenetic lineage B of the 
genus Beta-coronavirus and it recognizes the AC E2 as the entry recepto r (Zhou et al 2020). It 
is the seventh coronavirus known to cause hum an infections and th e third known to cause 
severe disease after SARS-CoV and MERS-CoV . 
Summaries of nonclinical pharm acology, PK, drug metabolism, and toxicology of AZD7442 
are provided in the AZD7442 IB. 
2.3 Benefit/Risk Assessment 
More detailed information about the known a nd expected benefits and potential risks of 
AZD7442 can be found in the AZD7442 IB. 
2.3.[ADDRESS_237077] 
RBD of the SARS-CoV-2 spi[INVESTIGATOR_198609]. Neither mAb has any 
human target. There are no potential risks based on mech anism of action. 
Potential risks are associated  with the administration of  any immunoglobulin, including 
polyclonal immunoglobulin preparations and mAbs. 
The important potential risks a ssociated with the administra tion of immunoglobulin, include, 
but are not limited to, anaphylaxis and othe r serious hypersensitivity reactions, including 
immune complex disease.  CCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY31 of 115  x Persons aged < [ADDRESS_237078] one of the following conditions: 
 Cancer 
 Chronic lung disease or m oderate to severe asthma 
 Overweight (defined as a body mass index (BMI) > 25 kg/m2 but < 30 kg/m2) or 
REHVLW\%0,¬ïNJP2); may be based on self-report of recent height and weight 
measurement) 
 Hypertension 
 Cardiovascular disease (inc luding history of stroke) 
 Diabetes 
 Chronic kidney disease 
 Chronic liver disease 
 Immunocompromised state from solid organ transpla nt, blood or bone marrow 
transplant, immune deficien cies, HIV, use of corticosteroids, or use of other 
immunosuppressive medicines 
 Sickle cell disease 
 Smoking (current or former) 
 
Randomization will be stratified (using centralized blocked randomization) by: 
1 7LPHIURPV\PSWRPRQVHW ¬îGD\VYHUVXV!GD\V  
2 High-risk versus low-risk of progression to se vere COVID-19 (high-ri sk is defined above) 
 
The enrollment of low-risk  participants has stopped. 
Up to approximately 1700 participants will be ra ndomized in a 1:1 ratio to receive a single IM 
dose of 600 mg of AZD7442 (n = up to a pproximately 850) or placebo (n = up to 
approximately 850) on Day 1. The first 20 participants  to be dosed at selected sites will form a 
sentinel group. To ensure balanced size of the two treatment groups in the sentinel group, 
randomization of these sentinel participants will be in a 1:1 ratio without  stratification. After 
the entire sentinel group has been dosed, furt her enrollment will pause until the sentinel 
group‚Äôs safety data through Day 8 has been re viewed by [CONTACT_198646] a 
recommendation to continue or to ha lt dosing of additional participants. 
Participants will be enrolled into one of 2 independent cohorts: 
x Cohort 1 (n = approximately 300), which wi ll include the sentinel group, will undergo 
more intensive testing to char acterize their viro logical and immunological status, and to 
correlate that status with clinical outcomes.  
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY32 of 115  x Cohort 2 (n = up to approximatley1400) will be followed for clinical outcomes.  
 
Following screening, and no more than 7 days from self-repor ted onset of COVID-19-related 
symptoms or measured fever, participants wi ll be randomized on Day 1 and receive a single 
dose of IMP. The dose will be administered as 2 separate IM injections (one for AZD8895 and 
one for AZD1061; the 2 compounds will not be co -administered) in the gluteal region. In 
Cohort 1, the first 20 participants  dosed (ie, the sentinel group ) will undergo safety monitoring 
for [ADDRESS_237079] participant in the sentinel group before 
the next participant can be dosed. The next 80 participants (21 to 100) will then undergo 
safety monitoring for [ADDRESS_237080] IMP administration, otherwise the minimum safety moni toring time will be 
1 hour. In addition, the sentinel group will be contact[CONTACT_198647] (in-person or by [CONTACT_756]) for 
the first [ADDRESS_237081] access to emerge ncy kits for treatment 
of severe anaphylactic reactions/shock and to medical staff trained in using these emergency 
kits.  
After administration of the dose of study inte rvention on Day 1, participants will undergo 
[ADDRESS_237082] been c onfirmed in the primary analysis population. A 
Day 169 analysis (additional efficacy and safety) will be conducted when all participants have 
been followed through Day 169. A final analysis w ill be conducted when all participants have 
completed the study. See Secti on 9.[ADDRESS_237083] completed the study if he/she  has completed all stages of 
the study, including the last sche duled procedure shown in the SoA (Table 1 for Cohort 1 and 
Table 2 for Cohort 2). 
The end of the study is defined as the date of the last scheduled procedure shown in the SoA 
for the last participant in the study globally. 
[ADDRESS_237084] a participant‚Äôs safety, physical 
or mental integrity, or scientific value will be classified as a serious breach. 
5.1 Inclusion Criteria 
Participants are eligible to be included in the study only if all of the following criteria apply: 
Age 
[ADDRESS_237085] be ¬ï [ADDRESS_237086] (antigen or  nucleic acid) from any respi[INVESTIGATOR_198610]HJRURSKDU\QJHDO13RUQ DVDOVZDERUVDOLYDFROO HFWHG¬îGD\VSULRUWR
Day 1. 
3 WHO Clinical Progression Scale score > 1 and < 4. 
[ADDRESS_237087] be dosed with IMP no more  than 7 days from self-reported onset of 
COVID-19-related symptoms (mild to moderate  COVID) or measured  fever, defined as 
the self-reported date of first reported sign/symptom from the following list: 
 Subjective fever or feeling feverish 
 Cough 
 Shortness of breath or difficulty br eathing at rest or with activity 
 Sore throat 
 Body pain or muscle pain/aches 
 Fatigue 
 Headache 
 Chills 
 Nasal obstruction or congestion 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY36 of 115   Nasal discharge 
 New loss of taste or smell 
 Nausea or vomiting 
 Diarrhea 
 Documented temperature > 37.8¬∞C/100¬∞F 
 New onset confusion (only for participants ¬ï 60 years old) 
 $SSHWLWHORVVRUGHFUHDVHGIRRGLQWDNHRQO\IRUSDUWLFLSDQWV¬ï \HDUVROG  
 Increased supplemental oxygen requiremen t (only for participants on baseline 
supplemental oxygen) 
5 One or more of the following signs/symptoms must be pres ent within 24 hours prior to 
Day 1: 
 Cough 
 Sore throat 
 Shortness of breath or difficulty br eathing at rest or with activity 
 Body pain or muscle pain/aches 
 Fatigue 
 Headache 
 Chills 
 Nasal obstruction or congestion 
 Nasal discharge 
 Nausea or vomiting 
 Diarrhea 
 New loss of taste or smell 
6 2[\JHQDWLRQVDWXUDWLRQRI¬ï REWDLQHGDWUHVWE\VWXG\VWDII ZLWKLQKRXUVSULRUWR
Day 1, unless the potential participant regu larly receives chronic supplementary oxygen 
for an underlying lung condition. 
Participation in another COVID-[ADDRESS_237088]. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY37 of 115  Reproduction 
8 Contraceptive use by [CONTACT_198654]. 
(a) Male participants: Contracepti on for male participants is not required; however, to 
avoid the transfer of any fl uids, all male participants must use a condom from Day 1 
and agree to continue through 90 days  following administration of IMP. 
(b) Female participants: 
 Women not of childbearing potential ar e defined as women who are either 
permanently sterilized (h ysterectomy, bilateral oo phorectomy, or bilateral 
salpi[INVESTIGATOR_1656]), or who are postmenopa usal. Women will be considered 
postmenopausal if they have been amenorrh eic for 12 months prior to the planned 
date of randomization without an a lternative medical cause. The following 
age-specific requirements apply: 
o Women < [ADDRESS_237089] been 
amenorrheic for 12 months or more fo llowing cessation of exogenous hormonal 
treatment and follicle-sti mulating hormone levels in  the postmenopausal range. 
o :RPHQ¬ï\HDUVROGZRXOGEHFRQV LGHUHGSRVWPHQRSDXVDOLIWKH\ KDYHEHHQ
amenorrheic for 12 months or more following cessation of all exogenous 
hormonal treatment. 
 Women of childbearing potential  must use one highly effectiv e form of birth control. 
A highly effective method of contraception is defined as  one that can achieve a 
failure rate of less than 1% per year when  used consistently and correctly. Women of 
childbearing potential who are sexually activ e with a non-sterilized male partner must 
agree to use one highly effe ctive method of birth contro l, as defined below, from 
Day 1 and agree to continue through 365 da ys following administration of IMP. 
Cessation of contraception afte r this point should be di scussed with a responsible 
physician. Periodic abstinence (calendar, symptothermal, post- ovulation methods), 
withdrawal (coitus interruptus), spermicides  only, and lactational amenorrhea method 
are not acceptable methods of contr aception. Female condom and male condom 
should not be used together. All women of childbearing pote ntial must have a 
negative pregnancy test result at Visit 1 a nd during the study as in the SoA (Table 1 
for Cohort 1 and Table 2 for Cohort 2). 
 
Examples of highly effective birth control methods are listed below. 
x Intrauterine device  
x Intrauterine hormone-rel easing system (IUS)  
x Bilateral tubal occlusion 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY38 of 115  x Vasectomized partner (provided that partner is the sole sexu al partner of the woman of 
childbearing potential study participant and th at the vasectomized partner has received 
medical assessment of the surgical success). 
x Sexual abstinence (sexual abstinence is c onsidered a highly effe ctive method only if 
defined as refraining from hete rosexual intercourse during th e entire period of the study 
and if it is the preferred and usua l lifestyle of the participant). 
x Combined (estrogen- and progestogen -containing hormonal contraception) 
 Oral (combined pi[INVESTIGATOR_4382]) 
 Injectable 
 Transdermal (patch) 
x Progestogen-only hormonal contraception 
 Oral 
 Injectable 
 Implantable 
 
Informed Consent 
9 Able to understand and comply  with study requirements/proce dures (if applicable, with 
assistance by [CONTACT_84452], surrogate, or legall y authorized representative) based on the 
assessment of the investigator.  
10 If able, signed informed consent. Ensure th at participants who are considered by [CONTACT_198655] a legally acceptable representative show evidence of assent, as 
applicable in accordance with local regula tions. See Appendix A for further details. 
 
5.2 Exclusion Criteria  
Participants are excluded from the study if  any of the following  criteria apply: 
Medical Conditions 
1 History or current hospi[INVESTIGATOR_198611]-19 [see also Appendix H for further 
guidance on the definitio n of hospi[INVESTIGATOR_059]]. 
2 Current need for hospi[INVESTIGATOR_198612] a clinic or emergency 
room service in the clinical  opi[INVESTIGATOR_198613] [see also Appendix H for 
further guidance on the defi nition of hospi[INVESTIGATOR_059]]. 
3 Previous hypersensitivity, infusion-related reaction, or severe adve rse reaction following 
administration of a mAb. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY39 of 115  4 Any prior receipt of investig ational or licensed vaccine or  other mAb/biologic indicated 
for the prevention of SARS-CoV-2 or COVID- 19 or expected administration immediately 
after enrollment 
5 Current requirement for mechanical ventil ation or anticipated impending need for 
mechanical ventilation. 
6 Clinically significant bleeding disorder (eg, factor deficien cy, coagulopathy, or platelet 
disorder), or prior history of significant bl eeding or bruising follo wing IM injections or 
venepuncture. 
[ADDRESS_237090] the ability of the participant 
to participate in the study, or impair interpretation of the study data. 
8 Known allergy/sensitivity or any hypersensitivity to com ponents of the IMP or placebo. 
9 Any co-morbidity requiring surgery within 7 days prior to study entry, or that is 
considered life-threatening in th e opi[INVESTIGATOR_198614] 30 days prior to 
study entry. 
Prior/Concomitant Therapy 
[ADDRESS_237091] udy entry. 
11 Receipt of convalescent COVID-19 plasma tr eatment at any time prior to study entry. 
12 Receipt of systemic steroids (eg, prednisone , dexamethasone) or inhaled steroids within 
30 days prior to study entry unless a stable dose used for a chronic condition. 
Prior/Concurrent Clinic al Study Experience 
13 Receipt of any IMP in the preceding 90 days or 5 half-lives, whichever is longer, or 
expected receipt of IMP during the period of study follow-up, or concurrent participation 
in another inte rventional study. 
Other Exclusions 
14 Judgment by [CONTACT_198656], restricti ons, and requirements. 
15 Previous randomization in the present study.  
16 For women only, currently pregnant (confirmed with positive pregnancy test) or breast 
feeding. 
17 Blood drawn in excess of a total of 450 mL (1 unit) for any reason with in [ADDRESS_237092] follow the contraception requirements outlined in Section 5.1. 
2 Restrictions relating to concomitant me dications are described in Section 6.5. 
 
5.4 Screen Failures 
Screen failures are defined as participants who c onsent to participate in the clinical study but 
are not subsequently randomly assigned to IMP. A minimal set of screen failure information is 
required to ensure transparent re porting of screen failure particip ants to meet the Consolidated 
Standards of Reporting Trials (CONSORT) publis hing requirements and to respond to queries 
from regulatory authorities. Mini mal information include s demography, screen  failure details, 
eligibility criteria, and any SAE. 
Individuals who do not meet the criteria for participation in th is study (screen failure) may be 
re-screened if the eligibility criterion that resu lted in screen failure has changed in a manner 
that meets eligibility. Only a single re-scr eening is allowed in the study. Re-screened 
participants should be assigne d the same participant number as for the ini tial screening. 
Individuals who are re-screened do no t need to re-consent for the study. 
6 STUDY INTERVENTION 
The IMP is defined as any inve stigational intervention(s), mark eted product(s), or placebo 
intended to be administered to or  medical device(s) utilized by  a study participant according to 
the study protocol. 
6.1 Investigational Medicinal Products Administered 
6.1.1 Investigational Medicinal Products 
Participants will be randomized in a 1:1 ra tio to receive one single 600 mg dose of AZD7442 
(administered as a 3 mL IM injection containing 300 mg AZD 8895 and a 3 mL IM injection 
containing 300 mg AZD1061) or saline place bo (administered as 2 separate 3 mL IM 
injections) (Table 4). Inves tigational medicinal product will be administered on Day 1, and 
participants will be monitored for [ADDRESS_237093]; IM Intramuscular; w/v Weight/volume. 
 
6.2 Preparation/Handling/Storage/Accountability 
[ADDRESS_237094] be stored in  a secure, environmentally 
controlled, and monitored (manual or automa ted) area in accordance with the labeled 
storage conditions, with access li mited to the investigator an d authorized site staff. 
[ADDRESS_237095] itution (where a pplicable) is 
responsible for IMP accountabi lity, reconciliation, and record maintenance (ie, receipt, 
reconciliation, and final disposition records). 
 CCI
CCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY42 of 115  6.2.1 Dose Preparation and Admi nistration Instructions 
Each vial selected for dose pr eparation should be inspected. If there are any defects noted with 
the IMP, the investigator and site mo nitor should be notified immediately. 
AZD7442 (AZD8895 and AZD1061) or placebo shoul d be administered in tramuscularly with 
one 3.0 mL injection in each gluteal re gion. The 2 drug products, AZD8895 and AZD1061 
(comprising AZD7442), must both be  administered separately to the participant in sequential 
order, with no participant receiving doses of AZD8895 without also receiving the matching 
dose of AZD1061. Refer to Handling Instruct ions for detailed dose preparation and 
administration information.  
6.3 Measures to Minimize Bias: Randomization and Blinding 
6.3.1 Randomization 
All participants will be centra lly assigned to randomized IMP using an IRT. Before the study 
is initiated, user guides, the l og in information, and directions for the IRT will be provided to 
each study site. Randomization will  be stratified (using centra lized blocked randomization) 
by: 
1 7LPHIURPV\PSWRPRQVHW¬î  5 days versus > 5 days) 
2 High-risk versus low-risk of progression to severe COVID-19 (high- risk is defined in 
Section 4.1) 
The enrollment of low-risk  participants is stopped. 
Where a participant does not meet all the eligibil ity criteria but incorrectly received IMP, the 
investigator should inform the Study Physicia n immediately, and a discussion should occur 
between the Study Physician and the investigator regarding whether to continue or discontinue 
the participant. 
6.3.[ADDRESS_237096] prior to dose 
preparation (due to differences  in container closure), IMP will be handled by [CONTACT_29646] (or designee, in accordance with lo cal and institutional re gulations) at the study 
site. Syringe masking will be required in order to maintain the blind. 
The randomization code should not be broken except in medical emergencies when the 
appropriate management of  the participant requires knowledge of  the treatment 
randomization, or in the instance a participant wishes to be considered for a SARS-CoV-[ADDRESS_237097] the immediate management of the 
participant‚Äôs condition (eg, antidote available), th e investigator has the sole responsibility for 
determining if unblinding of a participants‚Äô IMP assignment is warranted. Participant safety 
must always be the first consid eration in making such a deter mination. If a participant‚Äôs IMP 
assignment is unblinded, the Sponsor must be  notified within [ADDRESS_237098] under the guidance of  study personnel. The date (and time, if 
applicable) of dose administered in the clinic will be recorded in the source documents and 
recorded in the eCRF. If a problem occurs durin g dosing, such as needle break, no re-dosing is 
permitted. 
6.5 Concomitant Therapy 
Permitted, prohibited, and restricted me dications are summarized in Table 5. 
Any medication or vaccine (including over-the- counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at  the time of enrollment or 
receives during the study must  be recorded, along with: 
x Reason for use 
x Dates of administration, including start and end dates 
x Dosage information, in cluding dose and frequency 
 
The Study Physician should be contact[CONTACT_88451] e are any questions rega rding concomitant or 
prior therapy. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY44 of 115  Table 5 Summary of Permitted, Prohibited, or Restricted Medications 
Use Category Type of Medication/t reatment Timeline/instructions 
Permitted Routine vaccinesa Licensed influenza vaccines are permitted at any time. 
All other routine vaccines are permitted beginning 
> [ADDRESS_237099] 30 days 
prior to Day 1 and there is no anticipated change during 
the treatment period. Allergen immunotherapy should not 
be administered on the same day as IMP. 
Non-prescription treatments for allergies such as 
antihistamines, decongestants, and nasal steroids are 
permitted.  
Commercial biologics, 
prednisone, 
immunosuppressive 
medications (eg, azathioprine, tacrolimus, cyclosporine, 
methotrexate, 
hydroxychloroquine, or 
cytotoxic chemotherapy) Allowed, provided the participant is stable on 
maintenance dose (at steady state) prior to Day 1 and up 
to Day 29, OR  
Allowed if participant is hospi[INVESTIGATOR_198615]-19 
Participants may take concomitant medications pr escribed by [CONTACT_198657]/or for health maintenance. Primary care 
providers, or where appropriate investigators, should prescribe appropriate concomitant 
medications or treatments deemed necessary to provide full suppo rtive care and comfort 
during the study.  
Prohibited ‚Ä¢  Investigational products 
indicated for the treatment 
or prevention of SARS-CoV-2 or 
COVID-19 
‚Ä¢ Hydroxychloroquine 
‚Ä¢ Chloroquine 
‚Ä¢ Ivermectin 
‚Ä¢ HIV protease inhibitors 
 ‚Ä¢ Note: For participants wh o become hospi[INVESTIGATOR_198616]-19, receipt  of approved/licensed 
treatment options are permitted and they should be treated according to local standard of care, including 
investigational agents under emergency use 
authorization or equivalent regulations. 
‚Ä¢ Use of hydroxychloroquine is acceptable if used 
chronically for autoimmune disease, and the dose is 
stable prior to Day 1 and up to Day 29. 
‚Ä¢ Use of chloroquine if used to treat a parasitic 
infection 
‚Ä¢ Use of ivermectin is acceptable if used to treat a 
parasitic infection 
‚Ä¢ HIV protease inhibitors are acceptable if used 
chronically for HIV infection,  and the dose is stable 
prior to Day 1 and up to Day 29. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY45 of 115  Table 5 Summary of Permitted, Prohibited, or Restricted Medications 
Use Category Type of Medication/t reatment Timeline/instructions 
‚Ä¢ COVID-19 vaccinea ‚Ä¢  It is expected that most participants in this trial 
would have a protective infection-induced immune 
response. At this time, we have no reason to believe that the protection afforded by [CONTACT_198658].  
‚Ä¢ If participants request vaccination, the procedures 
described below apply. 
Restricted Contraceptive methods See Section 5.1  
Blood/plasma donation Participants must abstain from donating blood or plasma 
from the time of informed consent for one year after dose 
of study drug.  
Ova/Sperm donation See Sections [IP_ADDRESS] and [IP_ADDRESS] 
a The potential impact of AZD7442 on COVID-19 vaccines is not known and has not been studied. See 
Section 6.5.1 for instructions on COVID vaccinations. 
COVID-19 Coronavirus disease 2019; HIV Human immunodeficiency virus; IMP Investigational medicinal 
product; SARS-CoV-[ADDRESS_237100] received COVID-19 vacc ination prior to study entry will be excluded 
from this study.  
During the study, when participants become eligib le for access to a SARS-CoV-2 vaccine, it is 
appropriate that they can discu ss with the investigator and othe rs after Day 30 so as to make 
an informed choice. The following considerations apply: 
x Participants should not receive vaccination with an anti-SARS-CoV-2 vaccine during 
their acute illness. 
 Participants in this study will have active COVID-[ADDRESS_237101] on acute 
COVID-19. 
x Participants in this study are unlikely to receive any benefit from vaccination with an 
anti-SARS-CoV-2 vaccine after recovery from COVID-19. 
 There is no evidence that shows that partic ipants will benefit from vaccination with 
an anti-SARS-CoV-2 vaccine after r ecovery from their acute COVID-19. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY46 of 115   After recovery from COVID-19, most partic ipants in this tr ial would have a 
protective infection-i nduced immune response. At this  time, there is no reason to 
believe that the protection afforded by [CONTACT_198659] l infection is less fre quent or less robust 
than the protection provided by [CONTACT_198660]. 
x Participants may wish to be vaccinated. If so, they may be unblinded as to their 
randomized investigational treat ment in this study as pe r study unblinding procedure 
(Section 6.3.3), counselled, and referred outsi de the study for poss ible vaccination. 
 Despi[INVESTIGATOR_198617] a rationale th at participants in this study are likely to 
benefit from receiving a SARS -CoV-2 vaccine, some may wish to be vaccinated. In 
such situations, after rec overy from their COVID-19, and appropriate counselling, 
such participants can be unblinded as to th eir randomized investigational treatment in 
this study. With that information, they can be furt her counselled: 
o Unblinded participants who received pl acebo should be advised that no study-
associated contraindication to receiving a vaccine exists. 
o Unblinded participants who received AZ D7442 should be advised that, in the 
presence of adequate neut ralizing antibody titers, an appropriate and effective 
response to the vaccine might be impaire d. Such participants should be advised 
to consider waiting an a ppropriate length of time (9 to 12 months) before 
receiving an anti-SARS-CoV-[ADDRESS_237102] been unblinded in order to receive vaccination can and should remain 
in the study after being unblinded. 
6.6 Dose Modification 
The IMP will be administered  as described in Section 6.1.1. Dose modification is not 
permitted unless in case of discon tinuation of IMP, as per investig ator‚Äôs clinical judgment. Re-
administration of dose (re-cha llenge) is not permitted.  
6.7 Intervention After the End of the Study 
There is no intervention after the end of the study (see defin ition in Section 4.4). 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY47 of 115  7 DISCONTINUATION OF IMP AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL 
7.[ADDRESS_237103] 
Participants will receive a single dose of 6 00 mg AZD7442 (administered as a single IM 
injection containing 300 mg AZD8895 and a single IM injection containing 300 mg 
AZD1061) or saline placebo. 
It may be necessary for a participant to tempor arily interrupt their injection of IMP. If the 
injection of IMP is not resumed (ie, it is disc ontinued), the participant should remain in the 
study to be evaluated.  
Note that discontinuation of IMP is NOT the same thing as a withdrawal from the study. 
7.2 Participant Withdrawal from the Study 
x A participant may withdraw fro m the study at any time at his/ her own request, or may be 
withdrawn at any time at the discretion of  the investigator for safety, behavioral, 
compliance, or administrative reasons. This is expected to be uncommon. 
x A participant who consider s withdrawing from the study must be informed by [CONTACT_198661]-up options (eg, telephone contact, a contact [CONTACT_4490] a 
relative or treating physician, or in formation from medical records). 
x At the time of withdrawal from the study, if possible, an  Early Discontinuation visit 
should be conducted, as shown in the SoA (Table 1 for Cohort 1 and Table 2 for 
Cohort 2). See the SoA for data to be colle cted at the time of study withdrawal and 
follow-up and for any further evaluati ons that need to  be completed. 
x If the participant withdraws consent for disclo sure of future information, the Sponsor may 
retain and continue to use any data collect ed before such a wit hdrawal of consent. 
x If a participant withdraw s from the study, it should be confir med if he/she still agrees for 
existing samples to be used in line with the or iginal consent. If he/s he requests withdrawal 
of consent for use of samples, destruction of  any samples taken and not tested should be 
carried out in line with what was stated in the informed c onsent and local regulation. The 
investigator must document the decision on use of existing samples in the site study 
records and inform the Global Study Team. 
 
7.[ADDRESS_237104] be taken if a participan t fails to return to the clinic for a required 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY48 of 115  study visit: 
x The site must attempt to contact [CONTACT_31823] t and reschedule the miss ed visit as soon as 
possible and counsel the participant on the importance of maintain ing the assigned visit 
schedule and ascertain whether or not the partic ipant wishes to and/or should continue in 
the study. 
x Before a participant is  deemed lost to follow up, the inve stigator or designee must make 
every effort to regain contact  [CONTACT_6635] (where possible, 3 telephone calls and, 
if necessary, a certified letter to the participant‚Äôs last know n mailing address or local 
equivalent methods). These contact [CONTACT_24101]‚Äôs 
medical record. 
x Should the participant continue  to be unreachable, he/she will be considered to have 
withdrawn from the study.  
x Site personnel, or an independent  third party, will attempt to collect the survival status of 
the participant within legal and ethical boundaries for all participants randomized, 
including those who did not get the IMP. Pub lic sources may be searched for survival 
status information. If survival status is determined as dece ased, this will be documented 
and the participant will not be considered lo st to follow-up. Sponsor personnel will not be 
involved in any attempts to collect  survival status information. 
 
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix A. 
7.4 Study Suspension/Early Termination 
The Sponsor reserves the right to  temporarily suspend or perman ently terminate this study or a 
component of the study at any time. The reas ons for temporarily su spending the study may 
include, but are not limit ed to, the following: 
x Any death, SAE, or other safety finding assessed as related to  IMP that, in the opi[INVESTIGATOR_198618], may preclude furt her administration of IMP. 
x If one or more partic ipants experience a grade [ADDRESS_237105] 100 participants, experience a grade 3 or higher 
injection site reaction. 
 
In such a situation, no additional participants will be randomized or treated with IMP until 
review by [CONTACT_198662] (see Appendix A 5). 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY49 of 115  8 STUDY ASSESSMENTS AND PROCEDURES 
x Study procedures and their timi ng are summarized in the SoA (Table 1 for Cohort 1 and 
Table 2 for Cohort 2). Protocol waiver s or exemptions are not allowed. 
x Immediate safety concerns should be di scussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should cont inue or discontinue 
IMP. 
x Adherence to the study design requirements, including those specified in the SoA, is 
essential and require d for study conduct. 
x All screening evaluations must be complete d and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened a nd to confirm eligibility or record reasons for 
screening failure, as applicable. 
x Procedures conducted as part of the particip ant‚Äôs routine clinical  management (eg, blood 
count) and obtained before signing of the ICF may be utilized for sc reening or baseline 
purposes, provided the procedures have met the protocol-specified criteria and were 
performed within the timefr ame defined in the SoA. 
x The maximum amount of blood collected from each participant over the duration of the 
study, including any extra assessments that may be required, will not exceed [ADDRESS_237106] ed at each in-person visit. 
At study entry, if peripheral oxygen satu ration is < 92% on usua l supplemental oxygen 
requirements, the participant should be referr ed for emergency department evaluation and 
should not initiate IMP. 
During follow-up in-person visits (after  Day 1) through Day 29, peripheral oxygenation 
saturation measures < 96% should be reviewed by [CONTACT_198663]. 
The participant should be assessed for seve re COVID-19, characterized by a minimum of 
either pneumonia (fever, cough, tachypnea, or dy spnea, AND lung infiltrates) or hypoxemia 
(SpO 2 < 90% in room air and/or severe respi[INVESTIGATOR_13521] y distress) and a score of [ADDRESS_237107]/Update Secondary Contacts 
Sites will capture contact [CONTACT_198664] t [ADDRESS_237108] if the 
participant cannot be reached (eg, spouse, friend, neighbor). Sites will also request healthcare 
provider contact [CONTACT_198665][INVESTIGATOR_307](s) that the participant is likely to go to if they get 
sick. 
Contact [CONTACT_198666]. 
On Day [ADDRESS_237109]  the participant‚Äôs home address in  site records (it will not be 
reported on an eCRF). 
8.1.[ADDRESS_237110] person(s) or h ealthcare provider will be contact[CONTACT_5365] a check of the participant‚Äôs 
survival status. 
8.1.[ADDRESS_237111] be comple ted before administering IMP. Pa rticipants will be asked to 
complete subsequent entries in the diary each evening on Day 1 through 29 (the entry on 
Day 29 may be completed with the site staff dur ing the Day 29 visit, if the visit occurs on 
Day 29 versus another day in the Day 29 visit window). 
The diary will ask participants to report on the following: 
x Temperature 
x Shortness of breath 
x Difficulty breathing 
x Chills 
x Cough 
x Fatigue 
x Muscle aches 
x Body aches 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY51 of 115  x Headache 
x Loss of taste 
x Loss of smell 
x Sore throat 
x Congestion 
x Runny nose 
x Nausea 
x Vomiting 
x Diarrhea 
 
Symptom severity scoring will be based on the participant‚Äôs self-assessment. Participants 
should use the same self-determined appr oach to severity scoring each day. 
Only participants ¬ï 60 years of age will be asked to report on the following: 
x Have you felt as if you can‚Äôt think clearly? 
x Have you experienced any loss or decrease in appetite? 
x Do you take supplemental oxygen? 
x If yes, have you needed to increase  your supplemental oxygen intake? 
 
The participant-reported symptom diary is in Appendix G. 
In the event an electronic device is not availa ble when the participant is randomized, there will 
be a paper diary alternative w ith detailed instructions for pa rticipants and site staff. 
Diary Reminder and Sta ff Review of Diary 
Participant will be reminded every day through Da y 29 to complete their diary. This reminder 
will be received through the electronic device. 
The diary will be reviewed by [CONTACT_198667] 
(Table 1 for Cohort 1 and Table 2 for Cohort 2) . If an appropriate el ectronic system is 
available, the participant‚Äôs diary entries will auto matically be captured in the eCRF. If such a 
system is not available, the participant‚Äôs an swers on the diary will be transcribed into the 
eCRF. 
Participants who report worsening symptoms fr om any cause during the study may be referred 
to their healthcare provider or cl osest emergency room. Such instan ces will be recorded at the 
time of the notification, and dur ing follow-up to assess study endpoi nts, ie, hospi[INVESTIGATOR_198619]. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY52 of 115  Situations in which a COVID-19 sign or sympto m should be reported as an AE are described 
in Section 8.3.8. 
8.1.5 Return to Usual Health 
If the participant returns to usual (pre-COVID-19) health at any time through Day 169, the 
date will be recorded per the SoA (Table  1 for Cohort 1 and Table 2 for Cohort 2). 
  
 
 
 
 
At subsequent visits per the SoA (Table 1 for Cohort 1 and Table 2 for Cohort 2), participants 
will be asked if any new household members have been diagnosed with SARS-CoV-2 
infection, and the response  recorded on the eCRF. 
8.1.7 Virologic Studies 
Mid-turbinate nasal swabs and plasma will be  collected for qualitative and quantitative 
SARS-CoV-2 RNA assessment. 
 
Mid-turbinate Nasal Swabs 
Mid-turbinate nasal swabs will be taken at in-person visits per the SoA and will be analyzed 
centrally by [CONTACT_198668]-PCR assay (Table 1 for Cohort 1 and Table 2 for 
Cohort 2). The Day 1 swab should be co llected prior to the dose of IMP. 
 
 
 
8.2 Safety Assessments 
Planned time points for all safe ty assessments are provided in the SoA (Table 1 for Cohort 1 
and Table 2 for Cohort 2). 
8.2.1 Physical Examinations 
A complete physical examination will be perf ormed at screening, followed by a targeted or 
complete physical examination at subsequent visits per the SoA in Table 1 for Cohort 1 and CCI
CCI
CCI
CCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY53 of 115  Table 2 for Cohort 2. 
x A complete physical examination will include, but not be limited  to, assessment of height 
(screening only), weight, general appearance, he ad, ears, eyes, nose, throat, neck, skin, as 
well as cardiovascular, respi[INVESTIGATOR_696], abdominal , and nervous systems.  Each clinically 
significant abnormal finding at screening w ill be recorded in the medical history. 
x A targeted physical examination will incl ude areas suggested by [CONTACT_198669]. 
When there are no new complaints or findings this should be documented. Each clinically 
significant abnormal finding fo llowing randomization should be reported per Section 8.3 
(AE/SAE reporting). 
 
All physical examinations will be performed by a licensed healthcare provider (eg, physician, 
physician assistant, or li censed nurse practitioner). 
8.2.2 Vital Signs 
Vital signs, including pulse rate, pulse oximetry,  blood pressure, and body temperature will be 
performed at time points specified in the SoA (Table 1 for Cohort 1 and Table 2 for Cohort 2). 
The participant should be resting prio r to the collection of vital signs. 
Situations in which vital sign results should be reported as AE s are described in Section 8.3.6. 
8.2.3 Electrocardiograms 
A triplicate 12-lead ECG will be performed at time points specified in the SoA (Table 1 for 
Cohort 1 and Table 2 for Cohort 2). A 12-lead sa fety ECG will be obtained after 5 minutes‚Äô 
supi[INVESTIGATOR_198620], using the sites own ECG machines. 
The PI [INVESTIGATOR_198621]. If abnormal, it will be 
documented as to whether or not the abnormality is clinically significant by [CONTACT_978]. For all 
abnormalities (regardless of clinical significance), the sp ecific type and nature of the 
abnormality will be documented. Clinically significant findings should also be documented on 
the AE page of the eCRF, if applicable. 
The PI [INVESTIGATOR_198622] 12-lead resting ECG sa fety assessments if there are any abnormal 
findings or if the PI [INVESTIGATOR_198623] s it is required for a ny other safety reason. These assessments 
should be entered as an unscheduled assessment. 
All ECG readings will be digita lly stored as source documents. 
8.2.4 Clinical Safety Labo ratory Assessments 
Blood and urine samples for determination of clin ical chemistry, hemato logy, coagulation, and 
urinalysis will be taken at the visits indicated in the SoA (Table 1 for Cohort 1 and Table 2 for 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY54 of 115  Cohort 2). 
Additional safety samples may be collected, if clinically indicated, at the discretion of the 
investigator. The date and time of collection a nd results (values, units , and reference ranges) 
will be recorded on the appropriate eCRF. 
The clinical chemistry, hematology, and urinalys is will be performed at a central laboratory. 
Instructions for the collection and handling of the samples will be provided in the 
study-specific Laboratory Manual. If, due to COVI D-[ADDRESS_237112] certif ication for its jurisdiction.  
The following laboratory variables will be measured. 
Hematology  
White blood cell (WBC) count Neutrophils absolute count  
Red blood cell (RBC) count Ly mphocytes absolute count  
Hemoglobin (Hb) Monocytes absolute count  
Hematocrit (HCT) Eosinophils absolute count  
Mean corpuscular volume (MCV) Basophils absolute count  
Mean corpuscular hemoglobin (MCH) Platelets 
Mean corpuscular hemoglobin concentration 
(MCHC) Reticulocytes absolute count  
Serum Clinical Chemistry  
Sodium Alkaline phosphatase (ALP) 
Potassium Alanine aminotransferase (ALT) 
Urea Aspartate aminotransferase (AST) 
Creatinine Gamma glutamyl transpeptidase (GGT) 
Albumin Total Bilirubin 
Calcium Conjugated bilirubin 
Phosphate Creatine kinase 
Glucose  
C-reactive protein (CRP)  
Urinalysis  
Glucose Blood 
Protein Microscopy (if positive for protein or blood): 
RBC, WBC, Casts (Cellula r, Granular, Hyaline) 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY55 of 115  Coagulation  
International normalized ratio (INR) Prothrombin time (PT) 
Activated partial thrombin time (aPTT)  
NB. In case a participant shows an AST or $/7¬ï  3 √ó ULN together ZLWK7%/¬ï  2 √ó ULN please refer to 
Appendix D. Actions required in cases of increases in liver biochemistry and evaluation of Hy‚Äôs Law, for further 
instructions. 
TBL Total bilirubin; ULN Upper limit of normal.  
 
[IP_ADDRESS]  Females Only 
Pregnancy test (women of childbearing potential only) 
Serum human beta chorionic gonadotrophin 
(screening, at central laboratory) Urine human beta chorionic gonadotrophin 
(locally) 
Pregnancy test (suspected postmenopausal women < 50 years only) 
Follicle-stimulating hormone (FSH) (using serum at screening, at central laboratory) 
 
8.2.5 Injection Site Inspection 
An inspection of the injection sites should be performed on Day 1 (as according to Table 6), 
and at subsequent in-person visi ts up to and including Day 6 (see SoA in Table 1 for Cohort 1 
and Table 2 for Cohort 2). If eviden ce of injection site  reaction persists at  Day 6 visit, the 
injection site will be rechecked at each visit until no evidence of an active reaction remains. 
Table 6 Injection Site Inspection on Day 1 
Procedure/Time after both  injections have been 
administered Immediately 
after IMP 
administration 30 minutes 
(¬± 10 
minutes) Immediately 
prior to 
participant 
release 
Visual inspection of site X X X 
Palpation of site X X X 
Participant will be asked 
Are you experiencing any discomfort? X X X 
If yes, has the feeling of discomfort changed 
since you received the injection?  X X 
IMP Investigational medicinal product. 
 
Any AEs should be reported as described in Section 8.3. 
[IP_ADDRESS]  Monitoring After IMP Administration 
In addition to the injection site inspection, safety monitoring will be  performed after IMP 
administration. 
In Cohort 1, the first 20 participants dosed (i e, the sentinel group) will undergo safety 
Clinical Study Protocol - 7.[ADDRESS_237113] participant in the sentinel 
group before the next participant can be dosed. The next 80 participants (21 to 100) will 
undergo safety monitoring for [ADDRESS_237114] 4 days after IMP administration, the sentinel group will be contact[CONTACT_198647] 
(in-person or by [CONTACT_756]) to monitor AEs. 
8.3 Adverse Events and Serious Adverse Events 
The PI [INVESTIGATOR_198624]. 
The definitions of an AE or SAE can be found in Appendix B. 
Adverse events will be reported by [CONTACT_198670] (or, when appropriate, by a caregiver, 
surrogate, or the participant‚Äôs legally authorized representative).  
The investigator and any designees are respon sible for detecting, documenting, and recording 
events that meet the definition of an AE. 
8.3.[ADDRESS_237115] visit. 
If the investigator becomes awar e of a SAE with a suspected ca usal relationship to the IMP 
that occurs after the end of the clinical study in a participant treated by [CONTACT_198671], the 
investigator shall, without undue de lay, report the SAE to the Sponsor. 
8.3.2 Follow-up of AEs and SAEs 
Any AEs that are unresolved at the participant‚Äôs last AE assess ment in the study are followed 
up by [CONTACT_198672] r as long as medically indicated, bu t without further recording in the 
eCRF. [COMPANY_008] retains the right to request ad ditional information for any participant with 
ongoing AE(s)/SAE(s) at the end of the study, if judged necessary. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY57 of 115  Adverse event variables 
The following variables will be collected for each AE; 
x AE (verbatim) 
x The date and time when the AE started and stopped 
x Severity grade/maximum severity  
x Whether the AE is serious or not 
x Investigator causality rating against the IMP(s) (yes or no) 
x Action taken with regard to IMP 
x If the AE caused participant‚Äôs wi thdrawal from study (yes or no)  
x Outcome 
 
In addition, the following variab les will be collected for SAEs: 
x Date AE met criteria for SAE 
x Date investigator became aware of SAE 
x AE is serious due to 
x Date of hospi[INVESTIGATOR_059] 
x Date of discharge 
x Probable cause of death 
x Date of death 
x Autopsy performed 
x Causality assessment in rela tion to study procedure(s) 
x Causality assessment to other medication 
 
The following severity ratings will be used: 
x Grade 1: An event of mild intensity that is  usually transient and may require only minimal 
treatment or therapeutic inte rvention. The event does not ge nerally interfere with usual 
activities of daily living. 
x Grade 2: An event of moderate intensity that is usually alleviated with additional, specific 
therapeutic intervention. The even t interferes with usual activities of daily living, causing 
discomfort, but poses no signi ficant or permanent risk of harm to the participant. 
x Grade 3: A severe event that requires in tensive therapeutic in tervention. The event 
interrupts usual activities of dail y living, or significantly affect s the clinical status of the 
participant. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY58 of 115  x Grade 4: An event, and/or its immediate sequel ae, that is associated with an imminent risk 
of death. 
x Grade 5: Death as result of an event. 
 
It is important to distinguish between serious and severe AEs: 
x Severity is a measure of intensity, whereas seriousness is defined by [CONTACT_198673] B 2. 
x An AE of severe intensity need not necessa rily be considered serious. For example, 
nausea that persists for severa l hours may be considered severe nausea, but not an SAE. 
On the other hand, a stroke that results in only a limited degree of  disability may be 
considered a mild stroke, but would be an SAE. 
 
8.3.3 Causality Collection 
The investigator should asse ss causal relationship between IMP and each AE, and answer 
‚Äòyes‚Äô or ‚Äòno‚Äô to the question ‚ÄòD o you consider that there is a reasonable possibility that the 
event may have been caused by [CONTACT_2203]?‚Äô 
For SAEs , causal relationship should also be as sessed for other medication(s) and study 
procedures. Note that for SAEs that could be associated with any st udy procedure the causal 
relationship is implied as ‚Äòyes‚Äô. 
A guide to the interpretation of the caus ality question is found in Appendix B. 
8.3.[ADDRESS_237116] 
AESIs will be collected according to the time points specified in the SoA (see Table 1 for 
Cohort 1 and Table 2 for Cohort 2). 
AESIs are events of scientific and medical intere st, specific to the further understanding of the 
IMP safety profile, and require  close monitoring and rapid co mmunication by [CONTACT_198674]. An AESI can be serious or non-serious. All AESIs will be recorded in the 
eCRF. Serious AESIs will be recorded and reported as per Section 8.3.9. See also the 
AZD7442 IB, for additional information on AESIs. 
AESIs for AZD7442 are listed below. They include: 
x Anaphylaxis and other serious hypersensiti vity reactions, including immune complex 
disease 
x Injection site reactions 
 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY59 of 115  8.3.5 Adverse Events Based on Signs and Symptoms 
All AEs spontaneously reported by [CONTACT_198675] r, or reported in response to 
the open question from the study site staff: ‚ÄòHave you had any health problems since the 
previous visit/you were last asked?‚Äô, or revealed by [CONTACT_4171], will be collected and 
recorded in the eCRF. When collecting AEs, th e recording of diagnoses  is preferred (when 
possible) to recording a list of signs and symptoms. However,  if a diagnosis is known and 
there are other signs or symptoms  that are not genera lly part of the diagnosis, the diagnosis 
and each sign or symptom will be recorded separately. 
See Section 8.3.8 for the reporting of COVID-19-related symptoms. 
8.3.6 Adverse Events Based on Examinations and Tests 
The results from the protocol-mandated laborator y tests and other safety assessments will be 
summarized in the CSR.  
Deterioration, as compared to baseline in pr otocol-mandated safety assessments, should 
therefore only be reported as AEs if they fu lfil any of the SAE crit eria, are the reason for 
discontinuation of treatment with the IMP, or ar e considered to be clinically relevant, as 
judged by [CONTACT_093] (which may include, but is not limited to, consideration as to 
whether treatment or non-planned vi sits were required or other action was taken with the IMP, 
eg, dose adjustment or drug interruption).   
If deterioration in a laboratory va lue/vital sign is associated with clinical signs and symptoms, 
the sign or symptom will be reported as an AE  and the associated laboratory result/vital sign 
will be considered as additional information. Wherever possible the reporting investigator 
uses the clinical, rather than the laboratory te rm (eg, anemia versus low hemoglobin value). In 
the absence of clinical signs or  symptoms, clinically relevant  deteriorations in non-mandated 
parameters should be reported as AE(s). 
Any new or aggravated clinically relevant a bnormal medical finding at a physical examination 
as compared with the baseline  assessment will be reported as an AE unless unequivocally 
related to the disease under study. 
8.3.7 Hy‚Äôs Law 
Cases where a participant shows elevations in liver biochemistry may require further 
HYDOXDWLRQDQGRFFXUUHQFHVRI$67RU$/7¬ï  3 √ó 8/1WRJHWKHUZLWK7%/¬ï  2 √ó ULN and 
confirmed as a HL case should be reported as a SAE.  
$67RU$/7¬ï√Æ8/1WRJHWKHUZLWK7%/¬ï√Æ8/1ZKHUHQRRWKH UUHDVRQRWKHUWKDQWKH
IMP, can be found to explain the combination of increases (eg, elevated ALP indicating 
cholestasis, viral hepatitis, or another drug) should be evaluated. The elevation in 
Clinical Study Protocol - 7.[ADDRESS_237117] precede or be coincident with  (ie, on the same day) the elevation in TBL, 
but there is no specified timeframe within which the elevations in transaminases and TBL 
must occur. 
Please refer to Appendix D for further instructi on on cases of increases in liver biochemistry 
and evaluation of HL. 
8.3.8 Disease Under Study 
AZD7442 treatment studies will take a consistent approach to the handling of symptoms 
related to COVID-19, the disease under study. 
COVID-19 symptoms or signs, such as fever, cough, shortness of breath/difficulty breathing, 
sore throat, body/muscle pain, fa tigue, headache, chills, nasal obstruction or congestion, nasal 
discharge, new loss of taste or smell, naus ea, vomiting, diarrhea, new onset confusion (only 
for participants ¬ï\HDUVROGDSSHWLWHORVVRU GHFUHDVHIRRGLQWDNHRQO\IR USDUWLFLSDQWV
¬ï 60 years old), increased suppl emental oxygen requirement (only for participants on baseline 
supplemental oxygen) will be recorded as AEs when any of the following occur: 
x The sign or symptom is serious accordi ng to the definition in Appendix B 2. 
x The participant discontinues the st udy due to the sign or symptom. 
x In the investigator‚Äôs judgment , the sign or symptom is not considered COVID-[ADDRESS_237118] to be reported, whether or not co nsidered causally related to the IMP, or to the 
study procedure(s). All SAEs will be recorded in the eCRF. 
If any SAE occurs in the course of the study, in vestigators or other s ite personnel will inform 
the appropriate [COMPANY_008] representatives within one day ie, immediately but no later than 
[ADDRESS_237119] igators or other site personnel will inform 
[COMPANY_008] representatives of any follow- up information on a prev iously reported SAE 
within one calendar day, ie, immediately but no later than 24 hours of when he or she 
becomes aware of it. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY61 of 115  Once the investigators or other s ite personnel indicate an AE is serious in the EDC system, an 
automated email alert is sent to the designated [COMPANY_008] representative. 
If the EDC system is not availabl e, then the investigator or ot her study site staff reports a SAE 
to the appropriate [COMPANY_008] representative by [CONTACT_756]. 
The [COMPANY_008] representative will advise the investigator/study site staff how to proceed. 
The SAE must also be entered into the EDC system when it is available again. 
The reference document for defini tion of expectedness/listedness is the IB for the [COMPANY_008] 
drug. 
8.3.10  Pregnancy 
All pregnancies and outcomes of pregnancy should be reported to [COMPANY_008], except for: 
x If the pregnancy is discovered before th e study participant has received any IMP. 
 
[IP_ADDRESS]  Maternal Exposure 
The IMP should not be given to pregnant women.  
Pregnancy itself is not regarded as an AE unless there is a su spi[INVESTIGATOR_198625] a contraceptive medication. Congenital 
abnormalities/birth defects and s pontaneous miscarriages should be reported and handled as 
SAEs. Elective abortions without complications should not be handled as AEs. The outcome 
of all pregnancies (spontaneous miscarriage, el ective termination, ectopic  pregnancy, normal 
birth or congenital abnormality) should be follo wed up and documented even if the participant 
was discontinued from the study. 
If any pregnancy occurs in the course of the study , then the investigator or other site personnel 
informs the appropriate [COMPANY_008] representatives within one day , ie, immediately but no 
later than 24 hours of when he or she becomes aware of it. 
The designated [COMPANY_008] representative works with the investigator to ensure that all 
relevant information is provided to the [COMPANY_008] Patient Safety data entry site within one 
or 5 calendar days  for SAEs (see Section 8.3.9) and within [ADDRESS_237120] 365 
days after the IMP dose.  
[IP_ADDRESS]  Paternal Exposure  
Male participants should refrain from father ing a child during the study and for 365 days 
following the administration of IMP. 
In case of pregnancy of the partner of a male participant, the partner‚Äôs pregnancy should be 
reported on the pregnancy form (consent from the partner must be obtained before the 
pregnancy form is completed) following the same  timeframe and routing as described for any 
participant‚Äôs pregnancy. Pregnancy of the particip ant‚Äôs partner is not considered to be an AE. 
These pregnancies will also be followed up, a nd the outcome of the pregnancy (spontaneous 
miscarriage, elective termination, ectopic pregnancy, normal bi rth, or congenital abnormality) 
should, if possible, be ob tained and documented. 
Sperm Donation 
Male participants should not donate sperm for the duration of the st udy and for at least 365 
days after the IMP dose. 
8.3.11  Medication Error 
If a medication error occurs in the course of th e study, then the investigator or other site 
personnel informs the appropriate As traZeneca representatives within one day , ie, 
immediately but no later than 24 hours  of when he or she becomes aware of it. 
The designated [COMPANY_008] representative works with the investigator to ensure that all 
relevant information is completed within 1 (Initial Fatal/Life-Threatening or follow-up 
Fatal/Life-Threatening) or 5 (other serious initial and follow-up) calendar days  if there is an 
SAE associated with the medica tion error (see Section 8.3.9) and within 30 days  for all other 
medication errors. 
The definition of a Medication Erro r can be found in Appendix B 4.  
8.4 Overdose 
For this study, any dose of AZD7442  > 600 mg (ie, AZD8895 > 300 mg or 
AZD1061 > 300 mg) will be considered an overdose. 
[COMPANY_008] does not recommend a specific treatment for an over dose. Symptoms of overdose 
should be treated as pe r clinical judgment. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY63 of 115  x An overdose with associated AEs is reco rded as the AE diagnosis/symptoms on the 
relevant AE modules in the eCRF  and on the Overdose eCRF module 
x An overdose without associated symptoms is only reported on the Overdose eCRF 
module 
 
If an overdose on an [COMPANY_008] study interventi on occurs in the course of the study, the 
investigator or other site personnel info rm appropriate [COMPANY_008] representatives 
immediately, but no later than 24 hours  of when he or she becomes aware of it. 
The designated [COMPANY_008] representative works with the investigator to ensure that all 
relevant information is provided to the [COMPANY_008] Patient Safety data entry site within one 
or 5 calendar days  for overdoses associated with an SAE (see Section 8.3.9) and within 
[ADDRESS_237121] confidentiality . For further details on Handling of Human 
Biological Samples, see Appendix C. 
Samples will be stored for a maximum of 15 years from the date of the issue of the CSR in 
line with consent and local requi rements, after which they wi ll be destroyed/repatriated.  
x Pharmacokinetic samples will be disposed of after the Bioanalytical Report finalization or 
6 months after issuance of the draft Bioanalytical Report (whi chever is earlier), unless 
consented for future analyses.  
 Pharmacokinetic samples may be disposed  of or anonymized by [CONTACT_76435]. Additional 
analyses may be conducted on the anonymi zed, pooled PK sa mples to further 
evaluate and validate the analytical metho d. Any results from such analyses may be 
reported separately from the CSR. 
x Remaining ADA sample aliquots will be reta ined at [COMPANY_008] or its designee for a 
maximum of 15 years following issue of the CSR. Additional use includes but is not limited to further characterization of any A DAs, confirmation and/or  requalification of 
the assay as well as additional assay development work. The re sults from future analysis 
will not be reported in the CSR. 
 
8.5.1 Pharmacokinetics Assessments 
x Serum samples will be collected for measur ement of serum concentrations of AZD7442 
(AZD8895 and AZD1061), as specified in the SoA  (Table 1 for Cohort 1 and Table 2 for 
Cohort 2 ). 
Clinical Study Protocol - 7.[ADDRESS_237122] udy if warranted and 
agreed upon between the investigator and the Sponsor, eg, for safety reasons. The timing 
of sampling may be altered dur ing the course of the study ba sed on newly available data 
(eg, to obtain data closer to  the time of peak or trough matr ix concentrations) to ensure 
appropriate monitoring.  
x Serum samples will be used to analyze the PK of AZD7442. Samples collected for 
analyses of AZD7442 serum concentration may also  be used to evaluate safety or efficacy 
aspects related to concerns ar ising during or after the study. 
x Samples will be collected, labeled, store d, and shipped, as detailed in the Laboratory 
Manual. 
 
[IP_ADDRESS]  Determination of Drug Concentration 
Samples for determination of drug concentration in serum  will be assayed using an 
appropriately validated bioanalytical method. Full details of the analytical method used will be 
described in a separate  Bioanalytical Report. 
Placebo samples will not be analyzed, unless there is a need to confirm that correct treatment 
has been given to study participants.  
Drug concentration information that may unblind the study will not be reported to 
investigative sites or blinded personn el until the study has been unblinded. 
Incurred sample reproducibility analysis, if any, will be performed alongside the bioanalysis 
of the test samples. The results from the ev aluation, if performed, will be reported in a 
separate Bioanalytical Report. 
  
 
 
 
[IP_ADDRESS]  Anti-drug Antibody 
Blood samples for determination of ADA in se rum will be assayed using an appropriately 
validated bioanalytical method. Full details of the methods used will be described in a separate 
report. Samples will be collected, labeled, stor ed, and shipped, as detailed in the Laboratory 
Manual. 
[IP_ADDRESS]  SARS-CoV-2 Serology 
Serum samples will be collec ted to assess SARS-CoV-2 antig en-specific antibody levels from 
all participants according to the SoA (Table 1 for Cohort 1 and Table 2 for Cohort 2). Baseline CCI
CCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY65 of 115  serostatus and time to seroconversion in par ticipants receiving AZD7442 versus placebo may 
be determined in a validated  SARS-CoV-2 nucleocapsid anti gen assay operated by [CONTACT_198676]. Serologic assessment to  S (spi[INVESTIGATOR_2531]), RBD, and nucleocapsid antigens 
may also be assessed quantitatively using a validated multiplexed MSD immunoassay. 
  
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
  
  
 
 
 
 
 
 CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY66 of 115  8.6 Human Biological Sample Biomarkers 
8.6.1 Collection of Mandatory Samples for Biomarker Analysis 
By [CONTACT_198677], the pa rticipant consents to the mandatory research 
components of the study. 
Samples for biomarker research are required a nd will be collected from participants, as 
specified in the SoA (see Table 1 fo r Cohort 1 and Table 2 for Cohort 2).  
 
Details for samp le collection, 
processing, and testing will be provided in the Laboratory Manual. 
  
 
 
 
 
 
 
 
 
 
 
8.7 Medical Resource Utilizati on and Health Economics 
Medical resource utiliz ation and health economics are not applicable in this study. 
9 STATISTICAL CONSIDERATIONS 
9.1 Statistical Hypotheses 
The primary efficacy endpoint is a binary response whereby a partic ipant is classified as either 
having severe COVID-19 symptoms or death from any cause, or not. Efficacy will be 
FDOFXODWHGDVWKH555GHILQHGDV √≠5HODWLYH5LVN7KHQXOOK\S RWKHVLVLVWKH555RIVHYHUH
COVID-[ADDRESS_237123]  been confirmed in the primary analysis 
population. The type I error rate will be  controlled by a 2-sided alpha = 0.05. The 
methodology used to conserve al pha is detailed in Section 9.4.5. 
9.[ADDRESS_237124] 60% of participants 
will meet the protocol definition of being at hi gh-risk of progression to severe COVID-19 (see 
Section 4.1 for definition of high-risk). 
Note : ‚ÄúEnrolled‚Äù means a participant‚Äôs, or their legally acceptable representative‚Äôs, agreement 
to participate in a clinical  study following completion of th e informed consent process. 
Potential participants who are screened for the purpose of determining eligibility for the study, 
can be re-screened once. If they are not subseque ntly randomly assigned in the study, they are 
considered ‚Äúscreen failures‚Äù. 
Up to approximately 1700 participants, allowing for variability of the placebo groups primary 
endpoint event rate, will be randomized in a 1:1 ratio to receive a single IM 600 mg dose of 
AZD7442 (n = up to approximately 850) or place bo (n = up to approximately 850) on Day 1. 
 
 
 
 
 
 
This is an event-driven study with a primary analysis initia ted [ADDRESS_237125] a relative reduction  in  the incidence of severe COVID-
19/death between the study groups (AZD7442 vs placebo), 
 
9.3 Populations for Analyses 
The following populations ar e defined in Table 7. 
Table 7 Populations for Analysis 
Population/Analysis Set Description 
All participants analysis set  All participants screened for the study, to be used for reporting disposition 
and screening failures. CCI
CCI
CCI
CCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY68 of 115  Table 7 Populations for Analysis 
Population/Analysis Set Description 
Full analysis set All randomized participants who received IMP, irrespective of their 
protocol adherence and continued participation in the study. Participants 
will be analyzed according to their randomized treatment, irrespective of 
whether or not they have prematurely discontinued, according to the intent-
to-treat principle. Participants who wit hdraw consent or assent to participate 
in the study will be included up to the date of their study termination. 
Modified full analysis set All participants in the full analysis set ZKRUHFHLYHG,03¬îGD\VIURP
symptom onset and were not hospi[INVESTIGATOR_198626] ¬î'D\  for isolation 
purposes. 
Early intervention analysis set All participants in the modified full analysis set who received IMP ¬î [ADDRESS_237126] received IMP. 
Erroneously-treated participants (eg, those randomized to treatment A, but 
were actually given treatment B) are accounted for in this analysis set by 
[CONTACT_198678]. A participant who 
has received active IMP is classified as active. 
PK analysis set Dosed participants for whom an adequate (measurable drug concentration) 
PK profile has been obtained. All pa rticipants who r eceived AZD7442 and 
from whom PK blood samples are assumed not to be affected by [CONTACT_198679], and who had at least one quantifiable serum PK 
observation post-dose, will be included in the PK analysis dataset.  
Virology analysis set  The Virology analysis set consists of all participants in Cohort 1, who 
undergo more intensive virologic and immunologic assessments. 
Participants will be analyzed accord ing to their received treatment, 
irrespective of whether or not they have prematurely discontinued, 
according to the intent-to-treat principl e. Participants who withdraw consent 
or assent to participate in the study will be included up to the date of their 
study termination. 
IMP Investigational medicinal product; PK Pharmacokinetic. 
 
9.[ADDRESS_237127] important 
endpoints, including primary a nd key secondary endpoints. 
The study will be completely double-blind until the primary analysis (ie, blind for participants, 
Investigators/site staff, and S ponsor/designated clinical resear ch organization), in which case 
members of Sponsor/designated c linical research organization as sociated with the analysis, 
Clinical Study Protocol - 7.[ADDRESS_237128] or day-to-
day interactions with the site, will remain blinde d until the end of the study (ie, all participants 
have completed Day 457 visit) to ensure  the trial integrity is maintained. 
Categorical variables will be  summarized using frequency and percentages, where the 
denominator for calculation is the underlying analysis set popul ation, unless otherwise stated. 
Continuous variables will be summarized with descriptive st atistics of number  of available 
observations, mean, standard deviation, media n, minimum and maximum,  and quartiles where 
more appropriate. 
All point estimates will be presented with a 95% CI, unless otherwise stated. P-values, 
corresponding to a 2-sided test, will be pres ented for comparisons between treatments. 
  
 
 
 
 
 
 
 
 
9.4.2 Efficacy  
[IP_ADDRESS]  Primary Endpoint(s) 
The primary efficacy endpoint is a composite of either severe COVI D-19 or death from any 
cause through Day 29. Severe COVID-19 is ch aracterized by a minimum of either pneumonia 
(fever, cough, tachypnea, or dyspnea, AND lung infiltrates) or hypoxemia (SpO 2 < 90% in 
room air and/or severe respir atory distress) and a WHO Clinic al Progression Scale score of 5 
or higher (Appendix F). 
The primary estimand will be used for the analys is of the primary efficacy endpoint. It will be 
based on participants in the modified full analysis set defined in Table 7.  
 
 
 CCI
CCI
CCI
CCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY70 of 115   
For the primary efficacy analysis, the strati fied CMH method will be used. The RR will be 
estimated by [CONTACT_198680], and the efficacy  will be calculated as the RRR = 100 √ó 
√≠55ZKLFKUHSUHVHQWVWKHSH UFHQWUHGXFWLRQLQLQFLGHQFHRI VHYHUH&29,' -19 or death 
from any cause in the AZD7442 group relative to the placebo group. The 95% 2-sided CI will 
be presented. Participants who do not have an  event and do not remain in the study until the 
Day [ADDRESS_237129] ra tios and their respec tive 95% CIs. The 
stratification factors will be included as covariates in th e Cox model. Absence of data 
following participants‚Äô withdrawal/lost to follow-up will be treated as missing and censored at 
the date of last known status. Additionally, the absolute risk reduction of AZD7442 with 
respect to placebo in preventing severe COVID- 19 or death from any cause at Day 29, will be 
presented, along with the 2-sided 95% CI using th e stratified Miettinen and Nurminen‚Äôs score 
method (Miettinen and Nurminen 1985).  CCI
CCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY71 of 115  [IP_ADDRESS]  Secondary Endpoint(s) 
The key secondary endpoint is a composite of either death fr om any cause or hospi[INVESTIGATOR_198627]-[ADDRESS_237130]-dose period (Day 1 to 
Day 169) and will be analyzed in participan ts in the modified full analysis set. 
 
 
 
 
 
  
For the key secondary efficacy analysis, the RRR will be calculated at Day 169, as described 
for the primary efficacy analysis. The analysis will be conducted once, when all participants 
complete their Day 169 visit. Th e point estimate of the RRR of the key secondary endpoint by 
[CONTACT_99213]7442 compared to placebo, as well as th e 95% CI, will be calculated and reported 
following the same methodology as described fo r the primary efficacy  analysis. The null 
hypothesis that ‚Äúthe RRR of the key secondary efficacy endp oint by [CONTACT_99213]7442 compared to 
placebo is equal to zero‚Äù will be tested at an alpha level of 5%. The key secondary efficacy 
endpoint will only be considered statistically signifi cant if the statistica l significance of the 
primary efficacy endpoint and all supportive estimands for the primary endpoint is 
demonstrated. If the significance of the pr imary efficacy endpoi nt and all supportive 
estimands is not achieved, then the p-value for testing the key secondary efficacy endpoint 
will be considered nominal. 
To support the key secondary analysis, Kaplan-Mei er curves for time to death from any cause 
or first hospi[INVESTIGATOR_53763]-[ADDRESS_237131] ratios and their 
respective 95% CIs. The stratification factors will  be included as covariates in the Cox model. 
Other secondary endpoints, that are derived fro m binary outcomes or have binary outcome 
components, will be analyzed and reported sim ilarly using the primary analysis statistical 
method, except for detectability, and include: 
x The proportion of participants with respir atory failure, through Day 29, defined as a 
requirement for mechanical ve ntilation, ECMO, non-invasive ventilation, or high flow 
cannula oxygen delivery. CCI
Clinical Study Protocol - 7.[ADDRESS_237132] able SARS-CoV-2 over time (through Day 29) 
will be analyzed using a Kaplan-Meier analysis  for time to first undetectable result. This 
analysis will only be conducted in  the Virology analysis set.  
The proportion of participants who return to us ual health over time (through Day 29) will also 
be analyzed using a Kaplan-Meier analysis  for time to return to usual health. 
The only difference in the analys is and reporting of these seconda ry endpoints, compared to 
the key secondary endpoint, is  that all CIs and p-values will be considered nominal.  
For non-binary components and endpoints, th e following methods of analysis are planned. 
x The change from baseline of SARS-CoV-[ADDRESS_237133] at an alpha level of 5%. The Hodges-Lehmann estimate  and its 95% CI for 
the location shift between the [ADDRESS_237134]-baseline severity  score. For each symptom, the proportion of participants 
ZKRH[SHULHQFHGD¬ï -point reduction in severity fro m baseline to maximum severity 
post baseline will be tabulated. 
 
Details regarding the calculation of these endpoints and related imp utation (if applicable), will 
be described in the SAP. 
Specific technical details will be docu mented and explained in the SAP. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY73 of 115    
 
9.4.3 Safety 
[IP_ADDRESS]  Primary Endpoint(s) 
The safety of AZD7442 will pr imarily be assessed by: 
x Incidence of AEs through end of study 
x Incidence of SAEs through end of study 
x Incidence of AESIs through end of study 
 
AE intensity will be graded according to Appendix B 2. AEs will be presented for each 
treatment group by [CONTACT_198681]. Summaries will include the number 
and percentage of participants reporting at least one event, nu mber of events, and exposure 
adjusted rates, where appropriate. 
An overview of AEs will be presented for each treatment group, including the number and 
percentage of participants with any AE and SAEs. Summaries will present the relationship to 
IMP as assessed by [CONTACT_8647], maximum intensity, seriousness, and death. 
A listing will cover details for each individual AE . Full details of all AE analyses will be 
provided in the SAP. 
[IP_ADDRESS]  Other Safety Endpoint(s) 
x Laboratory parameters (hemat ology, clinical chemistry, co agulation, and urinalysis) 
x Vital signs (pulse rate, pulse oximetr y, blood pressure, and body temperature) 
x Physical examination 
x ECG 
 
Laboratory assessments will be performed for he matology, clinical chemistry, coagulation, 
and urinalysis parameters.  
All parameters from laboratory, vital signs,  physical examination, and ECG assessments will 
be summarized with descriptive statistics base d on data type (continuous , categorical, etc). No 
hypothesis testing or CIs will be performed or  calculated, unless otherwise specified. Full 
details of safety endpoints analys is will be provided in the SAP. 
   
  
 CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol - 7.[ADDRESS_237135] of subgroups includes but may not be limi ted to: age, sex, race, ethnicity, region, time 
from symptom onset to IMP, risk  groups defined as ‚Äòhigh‚Äô or ‚Äòlow‚Äô, comorbidity, baseline 
levels of vitamin D and zinc, sta ndard of care, and baseline sero status. Given data availability, CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol - 7.[ADDRESS_237136] 20 participants to be dosed (approxima tely 10 participants allocated to the AZD7442 
group and 10 allocated to the placebo group) and provide a recommendation to continue or to 
halt dosing of additi onal participants.  
The DSMB will make any necessary recomm endations to the Sponsor based on their 
evaluations of emerging safety data. For deta ils on the DSMB, refer to Appendix A 5. In 
addition, the composition and operation of the independent DSMB will be described in a 
DSMB Charter. 
[ADDRESS_237137] udy Oversight Considerations 
A 1 Regulatory and Ethical Considerations 
x This study will be conducted in accordance w ith the protocol and with the following: 
 Consensus ethical principles derived fro m international guide lines, including the 
Declaration of Helsinki and Council for International Organi zations of Medical 
Sciences (CIOMS) International Ethical Guidelines 
 Applicable ICH GCP Guidelines 
 Applicable laws and regulations 
x The protocol, protocol ame ndments, ICF, IB, and othe r relevant documents (eg, 
advertisements) must be sub mitted to an IRB/IEC by [CONTACT_198682]/IEC befo re the study is initiated. 
x Any amendments to the prot ocol will require IRB/IEC and applicable Regulatory 
Authority approval before implementation of  changes made to the study design, except 
for changes necessary to eliminate an immediate hazard to study participants. 
x [COMPANY_008] will be responsible for obtaini ng the required authorizations to conduct the 
study from the concerned Regulatory Authority. Th is responsibility may be delegated to a 
CRO but the accountability remains with [COMPANY_008]. 
x The investigator will be respons ible for providing oversight of  the conduct of the study at 
the site and adherence to requirements of  21 CFR, ICH guidelines, the IRB/IEC, 
European Regulation 536/[ADDRESS_237138] udies (if applicable),  European Medical 
Device Regulation 2017/745 for clinical device research (if applicab le), and all other 
applicable local regulations. 
 
Regulatory Reporting Requirements for SAEs 
x Prompt notification by [CONTACT_198683] a SA E is essential so that legal 
obligations and ethical responsibil ities towards the safety of pa rticipants and the safety of 
a study intervention under clinic al investiga tion are met. 
x The Sponsor has a legal responsibility to not ify both the local re gulatory authority and 
other regulatory agencies about the safety  of a study intervention under clinical 
investigation. The Sponsor w ill comply with country-speci fic regulatory requirements 
relating to safety reporting to the regulatory  authority, IRB/ IEC, and investigators. 
x For all studies except those utilizing medical de vices, investigator safe ty reports must be 
prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local 
regulatory requirements and Spons or policy and forwarded to i nvestigators as necessary. 
 European Medical Device Regulation 2017/ 745 for clinical device research (if 
applicable), and all other a pplicable local regulations 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY77 of 115  x An investigator who receives an investigator safety repo rt describing a SAE or other 
specific safety information (eg, summary or  listing of SAEs) from the Sponsor will 
review and then file it along with the IB and will notify the IRB/IEC, if appropriate 
according to local requirements. 
 
A 2 Financial Disclosure 
Investigators and sub-investigators will provide the Sponsor with suffic ient, accurate financial 
information as requested to allow the Sponsor  to submit complete and accurate financial 
certification or disclosure statements to the ap propriate regulatory au thorities. Investigators 
are responsible for providing information on fina ncial interests during th e course of the study 
and for one year after completion of the study. 
A 3 Informed Consent Process 
x The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized repr esentative and answer all questions regarding 
the study. 
x Participants must be informed that their part icipation is voluntary and they are free to 
refuse to participate and may withdraw th eir consent at any time and for any reason 
during the study. Participants or their legally authorized repres entative will be required to 
sign a statement of informed consent that meets the requirements of [ADDRESS_237139] 
(HIPAA) requirements, where applicab le, and the IRB/IEC or study center. 
x The medical record must include a statement that written informed  consent was obtained 
before the participant was enrolled in th e study and the date the written consent was 
obtained. The authorized person obtaining the in formed consent must also sign the ICF. 
x Participants must be re-consented to the most  current version of th e ICF(s) during their 
participation in the study. 
x A copy of the ICF(s) must be provided to the participant or the participant‚Äôs legally 
authorized representative. 
 
A participant who is re-screened is not required to sign another ICF. 
The ICF will contain a separate section that ad dresses and documents the collection and use of 
any mandatory and/or optional human biological  samples. The investigator or authorized 
designee will explain to each participant the ob jectives of the analysis to be done on the 
samples and any potential future use. Participants will be told that they are free to refuse to 
participate in any optional samples or the futu re use and may withdraw their consent at any 
time and for any reason duri ng the retention period. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY78 of 115  A 4 Data Protection 
x Participants will be assigned a unique identi fier by [CONTACT_1034]. Any participant records 
or datasets that are transferre d to the Sponsor will contain th e identifier only; participant 
names or any information, which would make the participant identifiable, will not be 
transferred. 
x The participant must be informed that his/her personal study-related data will be used by 
[CONTACT_198684]. The level of disclosure and use 
of their data must also be explained to the participant in the informed consent.  
x The participant must be informed that hi s/her medical records may be examined by 
[CONTACT_198685], by [CONTACT_6667]/IEC members, a nd by [CONTACT_163574]. 
 
A 5 Committee Structure 
The safety of all Sponsor clini cal studies is closely monitore d on an ongoing basis by [CONTACT_198686]. Issues identified wi ll be addressed; for 
instance, this could involve amendments to the CSP and letters to investigators. 
Data and Safety Monitoring Board (DSMB) 
An independent DSMB will monitor and protect th e safety of the participants throughout the 
study. The DSMB members will be selected fo r their expertise. The voting members of the 
DSMB will be comprised of external individuals, including the DSMB chair. Summaries of 
unblinded data will be prepar ed and provided to the DSMB . To minimize the potential 
introduction of bias, DSMB members will not have  direct contact [CONTACT_198687]. The data for review will be out lined in the DSMB Charter and will be agreed 
to in advance by [CONTACT_87110]. 
The DSMB will review safety data on a regul ar basis as set out in the DSMB Charter, 
including, but not limited to, reviewing the safety  data through Day 8 fro m all participants in 
the sentinel group.  
The DSMB can recommend modifications of the pr otocol to enhance part icipant safety and to 
recommend early termination of  the study if there is str ong evidence that AZD7442 or 
continuation of the study poses a sa fety concern to participants.  
A 6 Dissemination of Clinical Study Data 
A description of th is clinical study wi ll be available on 
http://astrazenecagrouptrials.pharmacm. com and http://www.clinicaltrials.gov  as will the 
summary of the study results when  they are available. The clin ical study and/or summary of 
study results may also be availa ble on other websites accordin g to the regulations of the 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY79 of 115  countries in which the study is conducted. 
A 7 Data Quality Assurance 
x All participant data relating to the study will be recorded on eCRF unless transmitted to 
the Sponsor or designee electronically (eg, laboratory data). Th e investigator is 
responsible for verifying that  data entries are accurate and correct by [CONTACT_198688]. 
x The investigator must maintain accurate do cumentation (source data) that supports the 
information entered in the eCRF. 
x The investigator must perm it study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents. 
x Monitoring details describing strategy (eg, risk -based initiatives in operations and quality, 
such as Risk Management and Mitigation Strategies and Analytical Risk-Based 
Monitoring), methods, responsibilities a nd requirements, including handling of 
noncompliance issues and monito ring techniques (central, remo te, or on-site monitoring) 
are provided in the relevant study plans. 
x The Sponsor or designee is res ponsible for the data manageme nt of this study, including 
quality checking of the data. 
x The Sponsor assumes accountability for acti ons delegated to other individuals (eg, 
CROs). 
x Study monitors will perform ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that 
the study is being conducted in accordance with  the currently approved protocol and any 
other study agreements, ICH GCP, and a ll applicable regulat ory requirements. 
x Records and documents, including signed ICFs , pertaining to the c onduct of this study 
must be retained by [CONTACT_1732] 15 years after study comp letion unless local 
regulations or institutio nal policies require a longer rete ntion period. No records may be 
destroyed during the retention period without  the written approval of the Sponsor. No 
records may be transferred to another location or party without written notification to the 
Sponsor. 
A 8 Source Documents 
x Source documents provide evidence for the exis tence of the participant and substantiate 
the integrity of the data collected. Source documents are filed at the investigator‚Äôs site. 
x Data entered in the eCRF that are transcribed  from source documents must be consistent 
with the source documents or the discrepancie s must be explained. The investigator may 
Clinical Study Protocol - 7.[ADDRESS_237140] been collected and a study-site closure visit has been performed. 
The investigator may initiate study-site closur e at any time, provided th ere is reasonable cause 
and sufficient notice is given in ad vance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_148709], but 
are not limited to: 
x Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the S ponsor‚Äôs procedures, or GCP guidelines 
x Inadequate recruitment of part icipants by [CONTACT_093] 
x Discontinuation of further st udy intervention development 
 
If the study is prematurely termin ated or suspended, the Sponsor  shall promptly inform the 
investigators, the IECs/IRBs, the regulatory au thorities, and any CRO(s ) used in the study of 
the reason for termination or  suspension, as specified by [CONTACT_56859]. The investigator shall promptly  inform the particip ant and should assure 
appropriate participant th erapy and/or follow-up. 
Participants from terminat ed sites will have the opportunity to be transferred to another site to 
continue the study. 
A [ADDRESS_237141] editorial and ethica l practice, the Sponsor  will generally support 
publication of multicenter studies only in their entirety and not as indi vidual site data. In 
this case, a co-ordinating investigator will be designated by [CONTACT_11402]. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY81 of 115  x Authorship will be determined by [CONTACT_14346]. 
 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY82 of 115  Appendix B  Adverse Events: Definitions a nd Procedures for Recording, 
Evaluating, Follow-up, and Reporting 
B [ADDRESS_237142] a causal relationship 
with this treatment. An AE can therefore be  any unfavorable and unintended sign (eg, an 
abnormal laboratory finding), symptom (for example nausea, chest pain), or disease 
temporally associated with the use of an IMP, whether or not considered  related to the IMP.  
The term AE is used to include both se rious and non-serious AEs and can include a 
deterioration of a pre-existing medical occurrence. An AE may occur at any time, including 
run-in or washout periods, even if no IMP has be en administered. 
B 2 Definition of Serious Adverse Events 
A SAE is an AE occurring during any study phase  (ie, run-in, treatment, washout, follow-up), 
that fulfils one or more of the following criteria: 
x Results in death 
x Is immediately life-threatening 
x Requires inpatient hospi[INVESTIGATOR_73606]  
x Results in persistent or significant disability or incapacity  
x Is a congenital abnormality or birth defect 
x Is an important medical event that may jeopa rdize the participant or may require medical 
treatment to prevent one of the outcomes listed above. 
 
Adverse events for malignant tumors  reported during a study should generally be assessed as 
SAEs . If no other seriousne ss criteria apply, the  ‚ÄòImportant Medical Even t‚Äô criterion should be 
used. In certain situations, how ever, medical judgment on an i ndividual event basis should be 
applied to clarify that the malignant tumor event should be  assessed and reported as a 
non-serious AE . For example, if the tumor is incl uded as medical hist ory and progression 
occurs during the study, but the progression does not change tr eatment and/or prognosis of the 
malignant tumor, the AE may not  fulfil the attributes  for being assessed as serious, although 
reporting of the progression of the malignant tumor as an AE  is valid and should occur.  Also, 
some types of malignant tumors, which do not sp read remotely after a routine treatment that 
does not require hospi[INVESTIGATOR_059], may be assessed as non-serious; examples in adults include 
Stage 1 basal cell carcinoma and Stage 1A1 cervical cancer remove d via cone biopsy. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY83 of 115  Life-threatening 
‚ÄòLife-threatening‚Äô means that the participant wa s at immediate risk of death from the AE as it 
occurred or it is suspected that use or c ontinued use of the product would result in the 
participant‚Äôs death. ‚ÄòLife-threaten ing‚Äô does not mean that had an AE occurred in a more severe 
form it might have caused deat h (eg, hepatitis that resolved  without hepatic failure). 
Hospi[INVESTIGATOR_198628] a SAE, although the reasons for it 
may be (eg, bronchospasm, laryngeal edema). Hosp ital admissions and/or  surgical operations 
planned before or during a study are not considered  AEs if the illness or disease existed before 
the participant was enrolled in the study, provide d that it did not deterior ate in an unexpected 
way during the study. 
Important Medical Event or Medical Treatment 
Medical and scientific judgment should be exerci sed in deciding whether a case is serious in 
situations where important medical  events may not be immediately life-threatening or result in 
death, hospi[INVESTIGATOR_059], disability, or incapacity , but may jeopardize th e participant or may 
require medical treatment to prevent one or more  outcomes listed in th e definition of serious. 
These should usually be considered as serious. 
Simply stoppi[INVESTIGATOR_198629]; medical 
judgment must be used. 
x Angioedema not severe enough to require in tubation but requiring iv hydrocortisone 
treatment 
x Hepatotoxicity caused by [CONTACT_76475] (ace taminophen) overdose requi ring treatment with 
N-acetylcysteine 
x Intensive treatment in an emergency room or at home for allergic bronchospasm 
x Blood dyscrasias (eg, neutrope nia or anemia requiring blood transfusion, etc) or 
convulsions that do not re sult in hospi[INVESTIGATOR_059] 
x Development of drug dependency or drug abuse 
 
Severity Rating Scale: 
x Grade 1: An event of mild intensity that is  usually transient and may require only minimal 
treatment or therapeutic inte rvention. The event does not ge nerally interfere with usual 
activities of daily living. 
x Grade 2: An event of moderate intensity that is usually alleviated with additional, specific 
therapeutic intervention. The even t interferes with usual activities of daily living, causing 
discomfort, but poses no signi ficant or permanent risk of harm to the participant. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY84 of 115  x Grade 3: A severe event that requires in tensive therapeutic in tervention. The event 
interrupts usual activities of da ily living, or significantly affect s the clinical status of the 
participant. 
x Grade 4: An event, and/or its immediate sequel ae, that is associated with an imminent risk 
of death. 
x Grade 5: Death as result of an event. 
 It is important to distinguish between serious  and severe AEs. Severity is a measure of 
intensity whereas seriousness is defined by [CONTACT_73010] B 2. An AE of severe 
intensity need not necessarily be considered serious. For example, nausea that persists for 
several hours may be considered  severe nausea, but not a SAE unless it meets the criteria 
shown in Appendix B 2. On the other hand, a stroke  that results in only a limited degree of 
disability may be considered a mild stroke but would be a SAE when it satisfies the criteria 
shown in Appendix B 2. 
B 3 A Guide to Interpreting the Causality Question 
When making an assessment of causality consider  the following factors when deciding if there 
is a ‚Äòreasonable possibility‚Äô that an AE may have been caused by [CONTACT_33641]. 
x Time Course. Exposure to suspect drug. Has the participant actually received the suspect 
drug? Did the AE occur in a r easonable temporal relationship to the administration of the 
suspect drug? 
x Consistency with known drug profile. Was th e AE consistent with the previous 
knowledge of the suspect drug (pharmacology and toxicology) or drugs of the same 
pharmacological class? Or, could the AE be anticipa ted from its pharmacological 
properties? 
x De-challenge experience. Did the AE resolv e or improve on stoppi[INVESTIGATOR_122570]? 
x No alternative cause. The AE cannot be reason ably explained by [CONTACT_11693], such as 
the underlying disease, other drugs, ot her host, or environmental factors. 
x Re-challenge experience. Did the AE reoccur if the suspected drug was reintroduced after 
having been stopped? [COMPANY_008] would not normally recommend or support a 
re-challenge. 
x Laboratory tests. A specific laboratory investigation (if performed) has confirmed the 
relationship. 
 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY85 of 115  In difficult cases, other factor s could be considered, such as: 
x Is this a recognized feature of overdose of the drug? 
x Is there a known mechanism? 
 
Causality of ‚Äòrelated‚Äô is made if, following a review of the re levant data, there is evidence for 
a ‚Äòreasonable possibility‚Äô of a causal relationship for the indi vidual case. The expression 
‚Äòreasonable possibility‚Äô of a causa l relationship is meant to convey,  in general, that there are 
facts (evidence) or arguments to  suggest a causal relationship. 
The causality assessment is performed ba sed on the available data, including enough 
information to make an informed judgment. With  no available facts or arguments to suggest a 
causal relationship, the event(s) will  be assessed as  ‚Äònot related‚Äô. 
Causal relationship in cases where the disease under study has deteriorated due to lack of 
effect should be classified as no reasonable possibility. 
B 4 Medication Error 
For the purposes of this clinical study, a medi cation error is an uninte nded failure or mistake 
in the treatment process for an [COMPANY_008] IMP th at either causes harm to the participant or 
has the potential to cause harm to the participant.  
A medication error is not lack of efficacy of the drug, but rather a human or process-related 
failure while the drug is in control of  the study site staff or participant. 
Medication error includes situ ations where an error:  
x Occurred 
x Was identified and intercepted before  the participant received the drug 
x Did not occur, but circumstances were rec ognized that could have led to an error 
 
Examples of events to be reported in clinical studies as medication errors: 
x Drug name [CONTACT_2976] 
x Dispensing error eg, medication prepared incorrectly, even if  it was not actually given to 
the participant 
x Drug not administered as indicated, for example, wrong route or wrong site of 
administration 
x Drug not taken as indicated eg, tablet dissolv ed in water when it should be taken as a 
solid tablet  
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY86 of 115  x Drug not stored as instructed eg, kept in the fridge when it should be at room temperature  
x Wrong participant received the medi cation (excluding IRT/RTSM errors) 
x Wrong drug administered to  participant (excludi ng IRT/RTSM errors) 
 
Examples of events that do not  require reporting as  medication errors in clinical studies: 
x Errors related to or resulting from IRT/RTSM ‚Äì including those which lead to one of the 
above listed events that would othe rwise have been a medication error  
x Participant accidentally missed drug dos e(s) eg, forgot to  take medication 
x Accidental overdose (will be captured as an overdose) 
x Participant failed to return unused  medication or empty packaging 
x Errors related to background and rescue medi cation, or standard of  care medication in 
open label studies, even if an [COMPANY_008] product  
 
Medication errors are not rega rded as AEs, but AEs may o ccur as a consequence of the 
medication error. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY87 of 115  Appendix C  Handling of Human Biological Samples 
C 1 Chain of Custody 
A full chain of custody is main tained for all samples thro ughout their life cycle. 
The investigator at each center keeps full traceab ility of collected biological samples from the 
participants while in storage at the center un til shipment or disposal (where appropriate) and 
records relevant processing information related to the samples while at the site. 
The sample receiver keeps full traceability of th e samples while in stor age and during use until 
used or disposed of or until further shipment an d keeps record of receipt of arrival and onward 
shipment or disposal. 
[COMPANY_008] or delegated representatives will ke ep oversight of the en tire life cycle through 
internal procedures, monitoring of study sites,  auditing or process checks, and contractual 
requirements of external  laboratory providers. 
Samples retained for further use will be stor ed in the [COMPANY_008]-assigned biobanks or other 
sample archive facilities and will be tracked by [CONTACT_198689]. 
If required, [COMPANY_008] will ensure that remaini ng biological samples are returned to the site 
according to local regulations or at the end of  the retention period, whichever is earlier. 
C 2 Withdrawal of Informed Consent for Donated Biological Samples  
[COMPANY_008] ensures that biological samples are re turned to the source or  destroyed at the end 
of a specified period, as descri bed in the informed consent. 
If a participant withdraws consen t to the use of donated biological samples, the samples will 
be disposed of/destroyed/repatriated, and the action documented. If samples are already 
analyzed, [COMPANY_008] is not obliged to destroy the results of this research. 
Following withdrawal of consent for biological samples, furthe r study participation should be 
considered in relation to the withdrawal pr ocesses outlined in the informed consent. 
The investigator: 
x Ensures participant‚Äôs withdraw al of informed consent to the use of donated samples is 
highlighted immediately to [COMPANY_008] or delegate. 
x Ensures that relevant human biological sample s from that participant, if stored at the 
study site, are immediately id entified, disposed of as appropriate, and the action 
documented. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY88 of 115  x Ensures that the participant and [COMPANY_008] are informed about the sample disposal. 
 
[COMPANY_008] ensures the organization(s) holdi ng the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of or repatriated as appropriate, 
and the action is documented a nd study site is notified. 
C [ADDRESS_237143] SAMPLES 
International Airline Trans portation Association (IATA) 
(https://www.iata.org/whatwedo/c argo/dgr/Pages/download.aspx ) classifies infectious 
substances into 3 categories: Category A, Category B, or Exempt 
Category A Infectious Substances are infectious substances in a form that, when exposure to 
it occurs, is capable of causing permanent disa bility, life-threatening or fatal disease in 
otherwise healthy humans or animals.  
Category A Pathogens  are, eg, Ebola, Lassa fever virus. Infectious substan ces meeting these 
criteria, which cause disease in humans or bot h in humans and animals, must be assigned to 
UN 2814. Infectious substances, which cause dis ease only in animals, mu st be assigned to 
UN 2900. 
Category B Infectious Substances are infectious substances that  do not meet the criteria for 
inclusion in Category A. Categor y B pathogens are, for example, Hepatitis A, C, D, and E 
viruses. They are assigned the followi ng UN number and proper shippi[INVESTIGATOR_72919]: 
x UN 3373 ‚Äì Biological Substance, Category B 
x are to be packed in accordance with UN 3373 and IATA 650 
 
Exempt ‚Äì Substances that do not contain infecti ous substances or substances which are 
unlikely to cause disease in human s or animals are not subject to these regulations, unless they 
meet the criteria for inclusion in another class. 
x Clinical study samples will fall into Cate gory B or exempt under IATA regulations 
x Clinical study samples will routinely be packed  and transported at ambient temperature in 
IATA 650 compliant packaging 
(https://www.iata.org/whatwedo/car go/dgr/Documents/DGR-60-EN-PI650.pdf ) 
x Biological samples transported in dry ice require additional dangerous goods specification 
for the dry-ice content 
 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY89 of 115  Appendix D  Actions Required in Cases of Incre ases in Liver Biochemistry 
and Evaluation of Hy‚Äôs Law 
D 1 Introduction 
This Appendix describes the process to be follo wed in order to identify and appropriately 
report Potential Hy‚Äôs Law (PHL) cases and HL case s. It is not intended to be a comprehensive 
guide to the management of el evated liver biochemistries.  
During the course of the study, the investigator  will remain vigilant for increases in liver 
biochemistry. The investigator is responsible  for determining whethe r a participant meets 
potential PHL criteria at any point during the study. 
All sources of laboratory data are appropriate for the determin ation of PHL and HL events; 
this includes samples taken at scheduled study vis its and other visits, in cluding central and all 
local laboratory evaluations, even  if collected outside of the study visits; for example, PHL 
criteria could be met by [CONTACT_198690] a central laboratory and/or  elevated TBL from 
a local laboratory.  
The investigator will also review AE data (eg, for AEs that may indicate  elevations in liver 
biochemistry) for possible PHL events. 
The investigator particip ates, together with [COMPANY_008] clinical project representatives, in 
review and assessment of cases m eeting PHL criteria to agree whet her HL criteria are met. HL 
criteria are met if there is no alternative explanation for the elevations in liver biochemistry 
other than Drug Induced Liver In jury (DILI) caused by [CONTACT_2203].  
The investigator is responsi ble for recording data pertai ning to PHL/HL cases and for 
reporting SAEs and AEs according to the outcome of the review and asse ssment in line with 
standard safety re porting processes. 
D 2 Definitions 
Potential Hy‚Äôs Law 
$67RU$/7¬ï  3 √ó ULN together with  7%/¬ï  2√ó ULN at any point during the study 
following the start of study medication irrespective of an increase in ALP.  
Hy‚Äôs Law 
$67RU$/7¬ï  3√ó ULN together with 7%/¬ï  2√ó ULN, where no other reason, other than the 
IMP, can be found to explain the combination of increases, eg, elevated ALP indicating 
cholestasis, viral he patitis, another drug.  
For PHL and HL the elevation in transaminases mu st precede or be coincident with (ie, on the 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY90 of 115  same day) the elevation in TBL, but there is no specified timeframe within which the 
elevations in transaminases and TBL must occur. 
D 3 Identification of Potential Hy‚Äôs Law Cases 
In order to identify cases of PHL it is impor tant to perform a comprehensive review of 
laboratory data for any participant who meets an y of the following identification criteria in 
isolation or in combination: 
x $/7¬ï  3 √ó ULN 
x $67¬ï  3 √ó ULN 
x 7%/¬ï  2 √ó ULN 
 
Central Laboratories Being Used: 
When a participant meets any of the PHL identification criteria, in  isolation or in combination, 
the central laboratory will immediately send an alert to the investigator (also sent to 
[COMPANY_008] representative).  
The investigator will also remain vigilant for any local laboratory reports where the PHL 
identification criteria are met; where th is is the case, the investigator will: 
x Notify the [COMPANY_008] representative 
x Request a repeat of the test (new blood draw) by [CONTACT_198691] 
x Complete the appropriate unscheduled laborator y eCRF module(s) with  the original local 
laboratory test result 
 
When the identification criter ia are met from central or local laboratory results, the 
investigator will, without delay: 
x Determine whether the particip ant meets PHL criteria (see Se ction D 2 for definition) by 
[CONTACT_198692] (inc luding both central and local 
laboratory results) 
 
If Local Laboratories Being Used: 
The investigator will, without  delay, review each new laboratory report and if the 
identification criteria are met, will: 
x Notify the [COMPANY_008] representative 
x Determine whether the particip ant meets PHL criteria (see S ection D 2 for definition) by 
[CONTACT_198693] - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY91 of 115  x Promptly enter the laboratory data into the laboratory eCRF 
 
D 4 Follow-up 
D 4.1  Potential Hy‚Äôs Law Criteria not met 
If the participant does not meet PHL criteria, the investigator will: 
x Inform the [COMPANY_008] representative that  the participant has not met PHL criteria 
x Perform follow-up on subsequent laboratory resu lts according to the guidance provided in 
the CSP 
 
D 4.2  Potential Hy‚Äôs Law Criteria met 
If the participant does meet PHL cr iteria, the investigator will: 
x Notify the [COMPANY_008] representative who w ill then inform the central Study Team  
x Within one day of PHL criteria being met, th e investigator will report the case as an SAE 
of Potential Hy‚Äôs Law; serious criteria  ‚ÄòImportant medical event‚Äô and causality 
assessment ‚Äòyes/related‚Äô according to CSP process for SAE reporting 
x For participants that met PHL criteria prior to starting IMP, the investigator is not 
required to submit a PHL SAE unless there is a significant change# in the participant‚Äôs 
condition 
x The Study Physician will contact [CONTACT_198694], discuss and agree 
an approach for the study pa rticipants‚Äô follow-up (including any further laboratory 
testing), and the continuous review of data 
x Subsequent to this contac t the investigator will: 
 Monitor the participant until liver biochemist ry parameters and appropriate clinical 
symptoms and signs return to normal or ba seline levels, or as long as medically 
indicated. Completes follow-up SAE Form as required. 
 Investigate the etiology of the event and perform dia gnostic investigations as 
discussed with the Study Physician. This in cludes deciding which the tests available 
in the HL lab kit should be used.  
 Complete the 3 Liver eCRF Modules as information becomes available  
 
#A ‚Äòsignificant‚Äô change  in the participant‚Äôs condition refers  to a clinically relevant change 
in any of the individual liver bi ochemistry parameters (ALT, AST,  or TBL) in isolation or in 
combination, or a clinically relevant change in associated symptoms. The determination of 
whether there has been a significant change will be at the discretion of the investigator; this 
may be in consultation with  the Study Physician if there is any uncertainty. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY92 of 115  D 5 Review and Assessment of Potential Hy‚Äôs Law Cases 
The instructions in this section should be foll owed for all cases where PHL criteria are met. 
As soon as possible after the biochemistry a bnormality was initially  detected, the Study 
Physician contacts the in vestigator in order to review av ailable data and agree on whether 
there is an alternative explan ation for meeting PHL criteria, other than DILI caused by [CONTACT_86184], to ensure timely analysis  and reporting to health authorities within [ADDRESS_237144] and TBL elevations, a 
determination of whether the alternative explanat ion is an AE will be made and subsequently 
whether the AE meets the criteria for a SAE: 
x If the alternative explanation is not an AE, record the alternative explanation on the 
appropriate eCRF 
x If the alternative explanation is an AE/SAE: update the prev iously submitted Potential 
Hy‚Äôs Law SAE and AE eCRFs accordingly with  the new information (reassessing event 
term; causality and seriousness criteria) fo llowing the [COMPANY_008] standard processes. 
 
If it is agreed that there is no explanation that would explain the ALT or AST and TBL 
elevations other than the IMP: 
x Send updated SAE (report term ‚ÄòHy‚Äôs Law ‚Äô) according to [COMPANY_008] standard 
processes.  
 The ‚ÄòMedically Important‚Äô se rious criterion should be used if no other serious 
criteria apply 
 As there is no alternative explanation fo r the HL case, a causality assessment of 
‚Äòrelated‚Äô should be assigned. 
 
If, there is an unavoidable delay, of over 15 calendar days in obt aining the information 
necessary to assess whether or not  the case meets the criteria for HL, then it is assumed that 
there is no alternative explanat ion until such time as an in formed decision can be made: 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY93 of 115  x Provides any further update to the previous ly submitted SAE of Potential Hy‚Äôs Law, 
(report term now ‚ÄòHy‚Äôs Law case‚Äô) ensuring cau sality assessment is related to IMP and 
seriousness criteria is medically important,  according to CSP process for SAE reporting. 
x Continue follow-up and review according to agreed plan. Once the necessary 
supplementary information is obtained, repeat  the review and assessment to determine 
whether HL criteria are still met. Update the previously submitted PHL SAE report 
following CSP process for SAE reporting, according to the outcome of the review and 
amending the reported term if  an alternative explanati on for the liver biochemistry 
elevations is determined. 
 
D [ADDRESS_237145] results need to be 
recorded. 
Hy‚Äôs Law Lab Kit for Central Laboratories  
Additional standard chemistry and coagulation tests GGT (Gamma glutamyl transpeptidase) 
LDH 
Prothrombin time 
INR 
Viral hepatitis IgM (immunoglobulin M) anti-HAV  
HbsAg 
IgM and IgG (immunoglobulin G) anti-HBc 
 
HBV DNA a 
IgG anti-HCV 
HCV RNA b 
IgM anti-HEV 
HEV RNA 
Other viral infections IgM & IgG anti-CMV 
IgM & IgG anti-HSV 
IgM & IgG anti-EBV 
Alcoholic hepatitis Carbohydrate deficient transferrin (CD-transferrin) c 
Autoimmune hepatitis Antinuclear antibody (ANA) 
Anti-Liver/Kidney Microsomal Ab (Anti-LKM) 
Anti-Smooth Muscle Ab (ASMA) 
Metabolic diseases alpha-1-antitrypsin 
Ceruloplasmin 
Iron 
Ferritin 
Transferrin c 
Transferrin saturation 
Clinical Study Protocol - 7.[ADDRESS_237146] 
ALP alkaline phosphatase 
ALT alanine aminotransferase/transaminase 
AST aspartate aminotransferase/transaminase 
AUC area under the curve 
BMI body mass index 
CDC Centers for Disease Control and Prevention 
CI confidence interval 
Cmax maximum concentration 
CMH Cochran-Mantel-Haenszel 
COVID-[ADDRESS_237147] 
ECG electrocardiogram 
ECMO extracorporeal membrane oxygenation 
eCRF electronic Case Report Form 
EDC electronic data capture 
Fc fragment crystallizable region 
)F»ñ5  Fc gamma receptor(s) 
FcRn neonatal Fc receptor(s) 
FTIH first time in human 
GCP Good Clinical Practice 
GLP Good Laboratory Practice 
HIV human immunodeficiency virus 
HL Hy‚Äôs Law 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY96 of 115  Abbreviation or special 
term Explanation 
IB Investigator‚Äôs Brochure 
IC50 50% maximal inhibitory concentration  
ICF informed consent form 
ICH International Council for Harmonisation 
IEC Independent Ethics Committee 
IgA immunoglobulin A 
IgG immunoglobulin G 
IM intramuscular 
IMP investigational medicinal product 
IRB Institutional Review Board 
IRT Interactive Response Technology 
IV intravenous 
mAb monoclonal antibody 
MERS-CoV Middle East respi[INVESTIGATOR_198630]-human primate 
NOAEL no-observed-adverse-effect level 
NP nasopharyngeal 
OF O'Brien Fleming 
PBMC peripheral blood mononuclear cell 
PD pharmacodynamic 
PHL Potential Hy‚Äôs Law 
PI [INVESTIGATOR_198631](s) 
RBD receptor binding domain 
RNA ribonucleic acid 
RR risk ratio 
RRR relative risk reduction 
RSV respi[INVESTIGATOR_198632]-PCR reverse transcription polymerase chain reaction 
RTSM Randomization and Trial Supply Management 
SAE serious adverse event  
SAP statistical analysis plan 
SARS-CoV-2 severe acute respi[INVESTIGATOR_7686]-coronavirus 2 
SoA Schedule of Activities 
SpO 2 oxygen saturation 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY97 of 115  Abbreviation or special 
term Explanation 
t1/[ADDRESS_237148] Vaccine-associated enha nced respi[INVESTIGATOR_198633] - 7.0 [COMPANY_008]
AZD7442 - D8851C00001
CONFIDENTIAL AND PROPRIETARY98 of 115Appendix F WHO Clinical Progression Scale for COVID-19
*If hospi[INVESTIGATOR_198634], record status as for ambulatory patient.
ECMO Extracorporeal membrane oxygenation; FiO2 Fraction of inspi[INVESTIGATOR_1401]; NIV Non-invasive ventilation; pO2 Partial pressure of oxygen; SpO2 Oxygen saturation. 
Source: WHO Working Group 2020
Note: See also Appendix H for further guidance on the definition of hospi[INVESTIGATOR_198635].

Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY99 of 115  Appendix G  Participant-reported Symptom Diary 
Clinical Study Protocol - 7.0 [COMPANY_008]
AZD7442 - D8851C00001
CONFIDENTIAL AND PROPRIETARY100 of 115

Clinical Study Protocol - 7.0 [COMPANY_008]
AZD7442 - D8851C00001
CONFIDENTIAL AND PROPRIETARY101 of 115

Clinical Study Protocol - 7.0 [COMPANY_008]
AZD7442 - D8851C00001
CONFIDENTIAL AND PROPRIETARY102 of 115

Clinical Study Protocol - 7.0 [COMPANY_008]
AZD7442 - D8851C00001
CONFIDENTIAL AND PROPRIETARY103 of 115

Clinical Study Protocol - 7.0 [COMPANY_008]
AZD7442 - D8851C00001
CONFIDENTIAL AND PROPRIETARY104 of 115

Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY105 of 115  Appendix H  Hospi[INVESTIGATOR_198636] a rising number of coronavirus diseas e 2019 (COVID-19) hospi[INVESTIGATOR_198637], leading to a shortage of hospi[INVESTIGATOR_198638], temporary facilities are being utilized 
increasingly to manage severe  COVID-[ADDRESS_237149] usually been treated in a 
traditional hospi[INVESTIGATOR_6885]. 
Please note that in the TACKLE  clinical study protocol, ‚Äúhos pi[INVESTIGATOR_059]‚Äù is defined as 
¬ï 24 hours of acute care, in a hospi[INVESTIGATOR_198639], including emergency 
rooms or temporary facilities instituted to address medical needs of  those with severe 
COVID-19 during the COVID-19 pandemic. 
As hospi[INVESTIGATOR_198640] y and key secondary 
endpoints in the study, further guidance is pr ovided regarding what constitutes these 
temporary facility or altern ate care sites used for managing participants with severe 
COVID-19. 
For the purposes of ascertaining an exclusion cr iterion or an endpoint ev ent, individuals with 
severe COVID-19 will be considered ‚Äúhospi[INVESTIGATOR_057]‚Äù if they are   
1 Managed in an alternative care site set up or authorized by [CONTACT_198695], pr ovinces or equivalent 
jurisdictions or  
2 Provided with acute hospi[INVESTIGATOR_198641] 
(a) Physician determines the patient‚Äôs conditi on as being appropria te for ‚Äúacute in-
patient hospi[INVESTIGATOR_059]‚Äù  
(b) Treating physician should have appropriate screening protocols before care at home 
begins, to assess both medi cal and non-medical factor s, including patient‚Äôs 
preference, working utilities and assessment of physical barriers 
(c) Patients are evaluated daily either in pers on or remotely by a qua lified health care 
provider/treating physician, a nd are managed appropriately  based on the patient‚Äôs 
treatment plan and local sta ndards for COVID-19 management. 
 
The appropriate WHO Clinical Progression Scal e for COVID-19 score assigned to grade the 
participant‚Äôs condition would depend on the le vel of oxygen/ventilation support provided in 
these acute care settings. 
 
Clinical Study Protocol - 7.[ADDRESS_237150] at the beginning of  the pandemic, therefore, the sample size, 
the RRR and assumed incidence of severe COVID-19/death have been reassessed.  
Synopsis, Sections 1.2 (Schema), 4.1 (Overall Design), 9.4.1 (General Considerations), 
9.5 (Interim Analysis), [IP_ADDRESS] (Primary E ndpoint(s)), 9.6 (Data Safety Monitoring 
Board) and A5 (Committee Structure):  To reflect the change in primary analysis and 
resulting time change the inter im analysis has been removed.  
Synopsis and Section 4.1 (Overall Design):  To improve participant enrollment the total 
number of sites has been cha nged from ‚Äòapproximately 85 to 95 sites‚Äô to ‚Äòapproximately 
130 to 140 sites‚Äô. 
Synopsis, Sections 4.1 (Overall Desi gn), 9.2 (Sample Size Determination) : As described 
above, sample size has been adjusted from "approx imately" 1700 participants to "up to 
approximately" 1700 participants, and the 95% power to detect  
 
 
Synopsis, Sections 4.1 (Overall Design), 9.1 (S tatistical Hypotheses ), 9.4 (Statistical 
Analyses), 9.4.1 (General Considerations ), [IP_ADDRESS] (Primary Endpoint(s)), Section 9.4.5 
(Methods for Multiple Testing Control ): As described above, th e primary analysis has 
been changed from ‚Äò90 primary endpoint  events‚Äô to ‚Äò30 days after the 52nd primary endpoint 
event‚Äô. Furthermore, enrollm ent will stop after the 52nd event has occurred. 
Synopsis, Sections 4.1 (Overall Design) and 6.3.1 (Randomization): In order to ensure 
the high-risk proportion of participants of more than 60% is reached enrollment of low-risk 
participants has stopped. To ma ke this clear, the statement ‚ÄòThe enrollment of low-risk 
participants has stopped‚Äô ha s been added to the CSP.   
Table 1 (Schedule of Activities for Cohort 2) and Table 2 (Schedul e of Activities for 
Cohort 2):  Due to the overlap in visit windows fo r Day [ADDRESS_237151] be performed on different days. According to the exploratory 
endpoints, the household infection report is only required through Day 169, and therefore, 
its collection has been removed from Day 366. 
Section 8.2.4 (Clinical Safety Laboratory Assessments) : Text added to confirm that sites CCI
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY110 of 115  primary analysis.  
Table 1 (Schedule of Activities for Cohort 1) and Table 2 (Schedul e of Activities for 
Cohort 2): Footnote updated to clarify that C OVID-[ADDRESS_237152] assessment is performed, rows labelled ‚ÄòECG‚Äô have been changed to 
‚ÄòTriplicate 12-lead ECG‚Äô. The Remote visit has been defined as either  a phone call or a 
web-based virtual assessment.  
To the symptom diary entry, the following f ootnote has been added:  ‚ÄòIf Day 29 visit is 
conducted earlier in ¬± 4 day window, participan t should retain sympto m diary in order to 
complete required daily en tries through Study Day 29‚Äô. 
Table 2 (Schedule of Activities for Cohort 2):  A footnote has been added to the IMP 
administration to describe re quired safety monitoring. This had been previously omitted 
from the CSP text.  
Sections 4.1 (Overall Design), 5.1 (Inclusion  Criteria), 5.2 (Exclusion Criteria), 8.3.10 
(Pregnancy), [IP_ADDRESS] (Maternal Exposure), Table 1 (Schedule of Activities for Cohort 1) and Table 2 (Schedule of Activities for Cohort 2):  Based on the low-risk to pregnant or 
breast feeding women and the potential benefit pregnant women may receive from mAb 
treatment the exclusion Crite rion 16, excluding pregnant a nd breast feeding women has 
been removed and inclusion Criterion 8(b) has been amended to remove  the requirement for 
a negative pregnancy test. Pregna ncy has also been added to the list of high-risk factors that 
can lead to progression to severe COVID-19.  
Section 5.1 (Inclusion Criteria):  In response to health aut hority feedback recommending 
that a minimum score of > 0 on th e clinical progression scale is  not appropriate, Criterion 3 
has been changed from ‚ÄòWHO Clinical Progr ession Scale score > 0 and < 4‚Äô to ‚ÄòWHO 
Clinical Progression Scale score > 1 and < 4‚Äô. 
Section 5.1 (Inclusion Criteria): To Criterion 4, the equivalent  Fahrenheit temperature has 
been added alongside Celsius.  
Section 5.1 (Inclusion Criteria):  To Criterion 8(a), condom use for male part icipants has 
been changed from ‚Äò365 days following admin istration of IMP‚Äô to ‚Äò90 days following 
administration of IMP‚Äô. As the mAbs have no human target and feta l TCR studies showed 
no mAb presence the risk of transmission is low,  and therefore the number of days has been 
reduced to reflect approximately 1 half-life.  
Section 5.2 (Exclusion Criteria):  To ensure that individuals likely to receive a vaccine 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY111 of 115  during their country‚Äôs immediate  roll out are not included in the study, Criterion 4 changed 
from ‚ÄòAny prior receipt of investigational or  licensed vaccine or  other mAb/biologic 
indicated for the prevention of  SARS-CoV-2 or COVID-19 or expected receipt during the 
period of study follow-up‚Äô to ‚ÄòA ny prior receipt of investigati onal or licensed vaccine or 
other mAb/biologic indicated fo r the prevention of SARS-CoV-2  or COVID-19 or expected 
administration immediately after enrollment‚Äô. 
Section 5.2 (Exclusion Criteria):  Criterion 5 language clar ified: ‚Äòrequirement for 
mechanical ventilation‚Äô changed to ‚Äòcurrent  requirement for mechanical ventilation‚Äô. 
Table 5 (Summary of Permitted, Prohibited, or Restricted Medications):  To avoid 
confusion at study sites, the table has been  updated with the follo wing clarifications:  
x Allergen immunotherapy should be allowed if  participant has been  receiving stable 
desensitization therapy for alle rgies for at least [ADDRESS_237153] been added to confirm that participants hospi[INVESTIGATOR_21391]-19 
may receive investigational ag ents under emergency use au thorization or equivalent 
regulations if available.  
x Blood/plasma donation is re stricted for one-year. 
 
Section 8.1.6 (Household Infection Report): Clarification to text that all members of a 
participant‚Äôs household should be cons idered for the infection report.  
Section 8.2.1 (Physical Examination) : To ensure the correct r ecording and implementation 
of the targeted physical examination, the te xt has been updated to confirm that where no 
new complaints or findings are observed this should be documented. Abnormal clinical 
findings after randomization should be reporte d per the AE and SAE reporting guidelines 
within the CSP.  
Sections 6.5 (Concomitant Therapy) and [IP_ADDRESS] (Maternal Exposure):  In response to 
health authority comments and for the safety of pa rticipants, restriction on ova donation for 
at least 365 days after IMP dosing has been added. 
Sections 6.5 (Concomitant Therapy) and [IP_ADDRESS] (Paternal Exposure):  In response to 
health authority comments and for the safety of pa rticipants, restrict ion on sperm donation 
for at least 365 days afte r IMP dosing has been added. 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY113 of 115  clarity to Investigators.  
Corrected typos are not listed above. 
 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY114 of 115  11 REFERENCES 
Ashraf-Kashani and Kumar 2017 
Ashraf-Kashani N, Kumar R. High-flow  nasal oxygen therapy. BJA Education. 
2017;17:57-62. 
CDC [ADDRESS_237154] of C OVID-19 during Pregnancy, available from 
https://www.cdc.gov/coronavirus/2019-ncov/ca ses-updates/special-populations/pregnancy-
data-on-covid-19/what-cdc-is-doing.html 
Gou and Xi [ADDRESS_237155] atistics in Biopharmaceutical Research. 
2019;11(4):398-406, DOI: 10.1080/19466315.2018.1546613. 
ICMRA 2020 
International Coalition of Me dicines Regulatory Authorities.  Global regulatory workshop on 
COVID-19 therapeutics: agreement on acceptabl e endpoints for clinical trials. Published 
online July 2020. Retrieved from http://ic mra.info/drupal/news/20july2020/summary 
Li 2016 
Li F. Structure, Function, and Evolution of  Coronavirus Spi[INVESTIGATOR_103184]. Annu Rev Virol. 
2016;3(1):237-61.  
Lilly BLAZE-1 2021 
Lilly. Lilly's bamlanivimab and etesevimab toge ther reduced hospi[INVESTIGATOR_198642] 3 trial for early COVID-19. Published online 10 March 2021. Accessed 31 March 2021. 
https://investor.lilly.com/n ews-releases/news-release-de tails/lillys-bamlanivimab-and-
etesevimab-together-reduced 
Miettinen and Nurminen 1985 
Miettinen O, Nurminen M. Co mparative analysis of two rates. Stat Med. 1985;4(2):213-26. 
Regeneron Pharmaceuticals, Inc. REGEN-COV Outpatient Trial 2021 
Regeneron Pharmaceuticals, Inc. Phase 3 trial shows Regen-Cov‚Ñ¢ (casirivimab with 
imdevimab) antibody cocktail reduced hospi[INVESTIGATOR_198643] 70% in non-hospi[INVESTIGATOR_198644]-19 patients. Published onlin e 23 March 2021. Accessed 31 March 2021. 
https://investor.regeneron.com/n ews-releases/news-release-deta ils/phase-3-trial-shows-regen-
covtm-casirivimab-imdevimab-
antibody#:~:text=This%20definitive%20P hase%203%20outcomes,71%25%20(2%2C400%20
mg%20IV) 
Clinical Study Protocol - 7.0 [COMPANY_008] 
AZD7442 - D8851C00001 
 CONFIDENTIAL AND PROPRIETARY115 of 115  Sharma et al 2020 
Sharma S, Danckers M, Sanghavi D, Chakra borty RK. High Flow Nasal Cannula. 2020 Jul 2. 
In: StatPearls [Internet]. Treasure Island (F L): StatPearls Publis hing; 2020 Jan‚Äì. PMID: 
30252327. 
Tamhane et al [ADDRESS_237156] a 
primary and a secondary endpoint  in a group sequential design with multiple interim looks. 
Biometrics. 2018;74(1):40-8. 
Weinreich et al 2021 
Weinreich DM, Sivapalasingam S, Norton T, Shazi a A, Gao H, Bhore, R, et al. REGEN-COV 
antibody cocktail clinical out comes study in Covid-19 outpati ents. medRxi: posted on line 
ahead of peer review. 06 June 2021. https://doi.org/10.1101/2021.05.19.21257469. 
WHO [ADDRESS_237157]. Availabl e from: https://covid19.who.int  
WHO Working Group [ADDRESS_237158] Dis. 2020;20:e192‚Äì97. Published Online June 12, 2020. DOI: 
https://doi.org/10.1016/S1473-3099(20)[ZIP_CODE]-7 
Zhou et al 2020 
Zhou P, Yang X-L, Wang X-G, Hu B, Zha ng L, Zhang W et al. A pneumonia outbreak 
associated with a new coronavirus of pr obable bat origin. Natu re. 2020;579(7798):270-3. 
Zou 2004 
Zou G. A modified poisson regression approach to  prospective studies with binary data. Am J 
Epi[INVESTIGATOR_5541]. 2004;159(7):702-6. doi:10.1093/aje/kwh090. PMID: 15033648 
 